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Abstract 
Global declines in malaria transmission in recent years have refocused efforts towards elimination. An 
essential part of this effort is adequate detection of transmission patterns. However, meta-analyses 
have shown that microscopy detects about half of all polymerase chain reaction (PCR)-confirmed 
infections. To date, the performance of rapid diagnostic tests (RDTs) relative to microscopy and PCR 
has not been evaluated in a comprehensive meta-analysis. Therefore, the relationship between PCR, 
RDT and microscopy prevalence estimates in asymptomatic populations was determined using data 
from cross-sectional surveys in endemic settings (Chapter 3). Overall, RDTs detected 41% of all PCR-
confirmed infections, and RDT-undetected (i.e. low-density) infections increased with age and 
decreasing transmission intensity.  
Another approach to estimate transmission is to use malaria-specific immune responses of resident 
populations as a measure of exposure to infection. Antimalarial antibodies, in combination with age, 
reflect both historical and recent exposure. Until recently, the majority of sero-surveillance data were 
based on a few well-characterised antigens using enzyme-linked immunosorbent assays (ELISA). 
However, which antibodies most accurately reflect exposure to recent low-density infections remains 
largely unknown. To address this, Chapter 4 examined antibody responses in previously naïve, 
controlled human malaria infections (CHMI) participants using protein microarray. Nearly all 
participants showed measurable antibody responses to a subset of four antigens one month post-
CHMI. In addition to protein microarray, multiplex bead assays (MBAs) enable multiplex detection of 
antibodies. However, MBA protocols may require further adaptation in scenarios where results must 
be readily available to inform control and elimination policies. The precision of an adapted MBA 
protocol with improved throughput and ease-of-use was determined in Chapter 5 using data collected 
in three large-scale transmission surveys. For some antigens, inter-plate variability seemed to increase 
during the third survey, possibly due to long-term storage of reagents. 
Commercially available ELISAs are standardised in their production and have been used to test blood 
products prior to donation to reduce the risk of transfusion-transmitted malaria. However, their 
performance in an epidemiological context has not been investigated. In Chapter 6, one of five 
commercially available ELISAs evaluated, accurately described transmission in a low transmission and 
pre-elimination setting. A low-cost, high-throughput assay for which results are readily interpretable 
may help to directly inform control activities targeting areas with remaining transmission.  
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Chapter 5 describes the data collection and quality control process for antibody detection from 
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CI  Confidence Interval 
cRDT  Conventional Rapid Diagnostic Test 
CSP  Circumsporozoite Protein 
DHS  Demographic and Health Surveys 
DNA  Deoxyribonucleic Acid 
EIR  Entomological Inoculation Rate 
ELISA   Enzyme-Linked Immunosorbent Assay 
FMM  Finite Mixture Model 
GMEP  Global Malaria Eradication Programme 
GR  Gametocyte Rate 
gSG6  Anopheles gambiae Salivary Gland Protein 6 
HBR  Human Biting Rate 
HMM  Hidden Markov Model  
HRP2  Histidine-rich Protein 2 
hs-RDT  High-Sensitive Rapid Diagnostic Test 
IFAT  Immunoﬂuorescence Antibody Test 
Ig  Immunoglobulin 
IQR  Interquartile Range 
IRS  Indoor Residual Spraying 
ITN  Insecticide-Treated Net 
IVTT  In Vitro Transcription and Translation 
LFA  Lateral Flow Assay 
LLIN  Long-Lasting Insecticide-treated Net 
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MalERA  Malaria Eradication Research and development Agenda 
MBA  Multiplex Bead Assay 
MDA  Mass Drug Administration 
MFI  Median Fluorescence Intensity 
MSAT  Mass Screen and Treat 
MSP-119 19 kilodalton fragment of Merozoite Surface Protein 1 
NAAT  Nuclear Acid Amplification Test 
OD  Optical Density 
PBS  Phosphate-Buffed Saline 
PCR  Polymerase Chain Reaction 
PFPf  Proportion of Fevers Plasmodium falciparum parasitaemic 
pLDH  Plasmodium Lactate Dehydrogenase 
POC  Point-of-care 
PR  Parasite Rate 
qPCR  Quantitative Polymerase Chain Reaction 
RDT   Rapid Diagnostic Test 
SCR  Seroconversion Rate 
SD  Standard Deviation 
SE  Schizont Extract 
SNP  Single Nucleotide Polymorphism 
SOP  Standard Operating Procedure 
SPR  Slide Positivity Rate 
SR  Sporozoite Rate 
SRR  Seroreversion Rate 
SSA  Sub-Saharan Africa 
USA  United States of America 
WHO  World Health Organisation 
 
Additional antigen abbreviations to those described above are detailed in Chapter 4, Supplementary 
Table 2 and Chapter 5, Table 1. 
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Chapter 1: Introduction 
 
1. Malaria Transmission: Control, Elimination & Eradication 
Malaria is a vector-borne infectious disease caused by the Plasmodium parasite of which P. falciparum 
and P. vivax pose the greatest public health challenge [1]. P. falciparum is the deadliest of human 
malarias and most prevalent in sub-Saharan Africa (SSA), while P. vivax mainly occurs in Southeast 
Asian and South-American settings [1,2]. Upon inoculation by an infectious mosquito, the malaria 
parasite develops in the human liver and then in the blood, where its replication causes malaria 
disease. Plasmodium transmission requires sexual-stage parasites, gametocytes, in humans to be 
taken up by female Anopheles mosquitoes when they feed. After a period of parasite development, 
mosquitoes can then infect humans again. A break in this cycle at any point interrupts malaria 
transmission, if this interruption occurs in sub-regions or countries it signifies elimination or, if 
globally, eradication [3,4]. During the 1950s/1960s the Global Malaria Eradication Programme (GMEP) 
successfully eliminated the disease from many temperate regions experiencing low transmission [5]. 
However, it failed in higher transmission areas as the available tools were insufficient to eliminate. 
Elimination efforts stagnated, and in some areas reversed, due to widespread insecticide resistance 
as well as technical, operational and financial reasons [5–8]. The following decades saw a worldwide 
increase in malaria incidence until in the late 90s/early 2000s increased investment led to the 
discovery of long-lasting insecticide-treated nets (LLINs), rapid diagnostic tests (RDTs) and artemisinin-
based combination therapies (ACTs) [9,10]. Between 2000 and 2015 these combined interventions 
have again resulted in impressive declines with infection prevalence halved in SSA alone [11]. In 2007, 
there was a renewed call to for malaria eradication and an up-to-date research agenda was defined 
[12,13]. However, drug and insecticide resistance due to the adaptation of the Plasmodium parasite 
and the Anopheles mosquito vector remain threats for control and elimination [14]. Even though more 
and more countries reach (pre-) elimination1 [16], there are several settings with persistent low 
malaria transmission2 despite high coverage of vector control measures and the availability of 
effective treatment, suggesting that novel approaches are needed for both surveillance and 
                                                          
1 Definition of pre-elimination: a phase of programme re-orientation from malaria control to elimination. Malaria 
programmes do not “achieve” pre-elimination status, they go through it, however an indicative milestone for 
finalisation and the move to the elimination phase is <1 case per 1000 population at risk per year [15]. 
2Definition of low transmission: annual parasite incidence (API) of 100-250 cases per 1000 population and 
prevalence of P. falciparum/P. vivax of 1-10%. Definition of very low transmission: API of <100 cases per 1000 
population and a prevalence of P. falciparum/P. vivax malaria >0 but <1% [17]. 
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interventions that will maintain and accelerate the elimination process [4,18,19]. For this, the ability 
to quantify malaria transmission accurately and rapidly is essential. With more countries globally 
reaching low or eliminating levels of malaria transmission we need to not only know how to reach 
zero transmission, but, intrinsically linked to this, how do we know transmission has ceased? 
The following section (Section 2) will present a short overview of key malaria metrics currently 
available to the malaria research and surveillance field. The Tables and Figure in this section are from 
the MalERA (Malaria Eradication Research and development Agenda) Refresh publication 
summarising the results from an expert consultative panel discussion on “Characterising the reservoir 
and measuring transmission”. I acted as rapporteur for this panel and was part of the writing 
committee for the resulting report published in 2017 [4]. The following two sections will firstly discuss 
the use of antimalarial antibodies as a metric to describe malaria transmission across populations 
(Section 3), and secondly the current laboratory methods for antibody detection that are used in the 
malaria research field (Section 4). Each section was published as a chapter in the Springer Encyclopedia 
of Malaria [20,21]. Any updates to the information in these two sections will be included in footnotes. 
The final section of the introduction (Section 5) will discuss the most recent updates to the sero-
surveillance field and constitutes original work.  
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2. Malaria Metrics 
Measures of malaria transmission can be defined at different points of the transmission cycle (Figure 
1). Most entomological metrics (Table 1) are unable to quantify, or differentiate changes in, the 
malaria burden at low transmission due to extremely low sporozoite rates in mosquitoes. As such 
entomology has been identified as a major neglected area critical to elimination [14]. Human metrics 
(Table 2) are divided into passive detection (in which malaria-infected patients seek care which leads 
to diagnosis) and active detection (in which health care workers or researchers screen for malaria-
infected patients, usually at their residence, by testing everyone willing to participate for malaria). 
Passively detected data are economically viable, on the basis of a health system with these services 
already being in place, as it provides continuous data over time [22]. However, this metric is 
dependent on the quality and coverage of the health system, health-seeking behaviour by local 
populations and the presence of symptoms during the infection. Active detection of malaria infections 
in a population circumvents these challenges (i.e. asymptomatic infections can be identified) and the 
most widely used metric is the parasite rate (PR): the proportion of people with an infection at a given 
point in time. However, active detection is more costly, labour-intensive and is usually a cross-
sectional (i.e. single-time-point) estimate. Moreover, the sensitivity of active detection in assessing 
the reservoir of infection within a population is dependent on the diagnostic used. Measuring parasite 
infection by microscopy has been the gold standard for malaria diagnosis for more than a century. 
More recently nuclear acid amplification tests (NAAT; most frequently polymerase chain reaction, 
PCR) as well as RDT are used. PCR-based techniques are considered impractical for field surveys due 
to the high costs, long processing time and the lack of appropriate facilities in many endemic countries 
[23]. However, Okell et al. showed in 2009 that approximately 50% of all PCR-infections were missed 
by microscopy [24] (i.e. submicroscopic infections). Submicroscopic infections were more prevalent in 
adults and at low transmission [25]. Although there is limited evidence of the role of submicroscopic 
infections in onwards transmission to mosquitoes and countries have eliminated malaria with the use 
of microscopy alone, their extent at low transmission has to be considered if our aim is to eliminate 
[4]. So far, no studies have performed a comprehensive meta-analysis to evaluate the concordance 
between PCR, RDT and microscopy detection methods simultaneously in asymptomatic populations. 
Furthermore, the detection of infections in cross-sectional surveys is heavily dependent on the timing 
of the survey, especially at low transmission, due to fluctuations in parasite rates between seasons 
and in parasite densities over the course of an infection. Serological metrics (discussed in detail below 
in Section 3), using antimalarial antibody responses in resident populations, are relatively new to the 
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malaria surveillance field. As antibodies represent past and therefore, cumulative, exposure, they can 
identify all those exposed to malaria in a single cross-section (Figure 2). 
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Figure 1. Key programmatic and research metrics across the malaria parasite transmission cycle. 
NAAT, nucleic acid amplification test; RDT, rapid diagnostic test; SNP, single nucleotide polymorphism. 
Figure copied from [4]. 
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Table 1: Summary of currently available entomological malaria transmission metrics. Table copied from [4]. 
Metric Definition [26] Measure of 
transmission 
Sampling method 
Resolution 
Discriminatory power 
Entomological 
inoculation rate 
(EIR) 
Number of infective bites received 
per person in a given unit of time, 
in a human population 
Transmission 
intensity 
• Human landing collection; 
light traps 
• Person or community level 
• Insensitive at low transmission 
• Lack of standardised sampling design 
• Collected by malaria control 
programmes 
Sporozoite rate 
(SR) 
Percentage of female Anopheles 
mosquitoes with sporozoites in the 
salivary glands 
Risk of infection • Human landing catch; baited 
traps; gravid traps 
• Community level 
• Insensitive at low transmission 
  
  
Human biting rate 
(HBR) 
Average number of mosquito bites 
received by a host in a unit time, 
specified according to host and 
mosquito species 
Risk of exposure • Human landing collection 
• Person or community level 
• Allows determination of the primary 
vector 
Vectorial capacity Rate at which given vector 
population generates new 
infections caused by a currently 
infectious human case 
Efficiency of 
transmission 
• Derived from human biting 
rate, parasite inoculation 
period, mosquito to human 
density and mosquito 
survival 
• Measures potential not actual rate of 
transmission – includes no 
parasitological information 
• Sensitive to changes in mosquito 
survival and biting behaviour, but 
may not translate to significant 
change in human incidence 
• Can be useful when infection rates 
are low and mosquito sampling 
difficult 
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Table 2: Summary of currently available malaria transmission metrics in humans. *No WHO definition available. Table copied from [4].  
Metric Definition [26] Measure of transmission Method  Discriminatory power 
Annual blood 
examination rate 
(ABER) 
The number of people receiving a 
parasitological test for malaria per unit 
population per year 
Level of diagnostic monitoring 
activity 
Microscopy 
or RDT 
• Dependent on health system provision 
Case, confirmed Malaria case (or infection) in which the 
parasite has been detected in a 
diagnostic test 
Current transmission or 
incidence if data collection is 
repeated or routine 
Microscopy 
or RDT 
positive 
• Insensitive at low transmission; 
saturates at high transmission 
• Underestimates due to system 
inadequacies and poor health-seeking 
behaviour 
Case, fever The occurrence of fever (current or 
recent) in a person 
Current transmission or 
incidence if data collection is 
repeated or routine 
Reported or 
observed 
fever 
• Overestimates malaria infection  
Proportion of fevers 
parasitaemic (PFPf)* 
Proportion of fever cases found to be 
positive for Plasmodium 
Current transmission or 
incidence if data collection is 
repeated or routine 
Microscopy; 
RDT; NAAT 
• Depends on diagnostic sensitivity 
• Insensitive at low transmission 
Slide positivity rate 
(SPR) 
Proportion of blood smears found to be 
positive for Plasmodium among all 
blood smears examined 
Current transmission or 
incidence if data collection is 
repeated or routine 
Microscopy • Depends on ABER 
• Insensitive at low transmission 
RDT positivity rate 
(RDT-PR) 
Proportion of positive results among all 
RDTs performed 
Current transmission or 
incidence if data collection is 
repeated or routine 
RDT • Depends on RDT sensitivity 
• Insensitive at low transmission 
Parasite rate (PR) Proportion of the population found to 
carry asexual blood-stage parasites 
Current transmission or 
incidence if data collection is 
repeated or routine 
Microscopy; 
RDT; NAAT 
• Depends on diagnostic sensitivity 
• Insensitive at low transmission 
Gametocyte rate (GR) Percentage of individuals in a defined 
population in whom sexual forms of 
malaria parasites have been detected 
Potentially infectious human 
population 
Microscopy; 
NAAT 
• Depends on diagnostic sensitivity 
• Insensitive at low transmission 
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Figure 2: Schematic of the information collected in six cross-sectional surveys assessing the parasite rate compared to one cross-sectional survey assessing 
antibody responses. For parasite rate surveys: grey people are parasite negative and red people are parasite positive. For the serological survey: grey people 
are antibody negative, while the shading of colours is indicative of antibody titre (those more recently infected have higher antibody titres represented in 
darker colours). 
Population surveyed for parasite rate every half year
Serology survey will detect antibodies in all those exposed
8% 0% 0% 4% 16% 4%
32%
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3. Immunoepidemiology for the Evaluation of Malaria 
Transmission Patterns 
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3 The use of “antibody loss” here refers to “reversion from seropositive to seronegative” (i.e. the dichotomous 
values) rather than antibody decay (i.e. loss of antibody density over time). 
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4 The term “more realistic” is intended to convey a higher SRR and therefore shorter estimates of the time to 
seroreversion. Bosomprah [27] showed an increase in the estimated SRR from 0.01393 (time to revert to 
seronegative approximately 72 years) to 0.0426 (23 years) using an extended catalytic model. 
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5 Furthermore, Reverse Cumulative Distribution Plots have been described as a methodology to analyse antibody 
data in 1995 [28] and applied in malaria epidemiological studies as a measure of change in transmission by Wong 
et al. [29]. More recently, mathematical models assessing the rate of antibody acquisition and loss using 
antibody density data have shown an increased precision of estimates of transmission patterns compared to 
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reversible catalytic models using dichotomous data [30–32]. 
6 The reference Wipasa et al. is incorrect here as they do not discuss AUC, however this methodology was 
published recently by Arnold et al. [30]. A rectification has been sent to Springer. 
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7 A highly sensitive (hs) histidine-rich protein II (HRP2)-based RDT has recently been developed with a reported 
limit-of-detection that is 10-fold more sensitive than that of conventional RDTs (cRDT). Assessment of its 
39 
 
                                                          
performance is ongoing in several field trials [33]. The only published results from a field trial to date are from 
eastern Myanmar where hs-RDT had a 2-fold greater sensitivity compared to cRDT while the specificity was 
similar using a combination of ultra-sensitive PCR and HRP2 ELISA as the reference standard. However, field 
sensitivity of the hs-RDT using the same combined reference standard was lower compared to laboratory 
assessments (35% versus 51%) which may be due to operational challenges [33,34]. 
8 Helb et al. have described antibody responses that can predict recent exposure to infection in a cohort of 
Ugandan children in 2015 [35]. This work and other publications assessing antibody responses associated with 
recent infection will be discussed in the final section of the introduction (Section 5). 
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9 The LFA described here is what is referred to as RDT in other sections of this thesis. Hereafter, LFA will only be 
used for those detecting antibodies against the malaria parasite while RDT will only be used for those detecting 
malaria parasite antigens: Plasmodium lactate dehydrogenase (pLDH) or HRP2. 
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4. Malaria Diagnostic Platform, Antibody Detection 
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10 Synonyms for the CBA in the literature are quantitative suspension array technology (qSAT), multiplex bead 
assay or array (MBA), and multiplex bead-based assay etc. Sometimes the brand name of the detection 
instrument is used: Luminex® or MAGPIX®. In this publication CBA was used, whereas in later thesis chapters 
MBA will be used. 
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11 I.e. comparatively high costs for equipment and consumables and the need for trained expert laboratory 
technicians. 
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12 Alternatively, a single dilution positive control sample or a single dilution of multiple positive control samples 
can be used. 
13 Herman et al. [36] and Krause et al. [37] have recently described P. knowlesi-specific proteins (both published 
in 2018). 
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14 Two sub-species of P. vivax have been identified: P. ovale curtisi and P. ovale wallikeri [38]. 
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5. Recent Developments in Multiplex Antibody Detection and 
its Role in Improving Sero-Surveillance 
The previous sections have summarised the limitations of existing metrics of malaria transmission in 
low endemicity settings. Submicroscopic infections (i.e. PCR positive, microscopy negative; defined 
here as low-density infections) are common in adults and at low transmission influencing the 
performance of PR measures. Whereas health-seeking behaviour, low-density and/or asymptomatic 
infections and the quality of the health system influence the sensitivity of passively collected data as 
a metric of ongoing transmission in communities. Antibody responses to well-characterised asexual 
stage antigens from malaria parasites represent cumulative exposure to infection and as such there is 
an increased sensitivity in detecting those exposed to malaria in cross-sectional surveys compared to 
repeated PR measures, which is especially of use at low transmission (Figure 2). Furthermore, the SCR 
has shown a stronger correlation with the EIR compared to PR measures (Figure 3). 
Until recently, the majority of sero-surveillance data was based on a few well-characterised antigenic 
targets (using ELISA) whereby certain populations might have been missed due to the highly variable 
nature in which the parasite presents itself to its host and of human immunological responses to 
malaria. For example, sporozoite antigens elicit measurable antibody responses but their traversal 
from the skin to the blood stream and migration to the liver is rapid (i.e. 15 min to a few hours; 
reviewed in [39]). Antibody responses to this parasite stage may be more biased towards IgM or IgA 
and are likely lower in titre than IgG responses to antigens from replicating blood stages. Even within 
the blood compartment, responses to antigens appear to differ widely. Helb et al. showed that 
commonly used antibodies to antigens such as AMA-1 and MSP-119 were not accurate predictors of 
recent infection or clinical incidence [35]. These targets are generally described as historical or long-
term markers owing to the fact that antibody responses to these antigens have estimated half-lives of 
23 years [27] to 50 years or more [40] for MSP-119, with limited data from observational studies 
suggesting 5-16 years (with 95% confidence intervals including infinity) [41]. As discussed, 
polymorphisms in the genetic coding for antigens is another example of the diversity in which the 
malaria parasite presents itself to its host which may affect antibody responses to specific antigens 
within and between resident populations exposed to different parasite populations. Age is a well-
known human determinant of the acquisition and longevity of antimalarial antibody responses. Other 
examples of the variation in human immunological responses to malaria are the described differences 
in Fulani and Dogon ethnic groups in Mali. Fulani have shown higher IgM and IgG titres to a wider 
range of P. falciparum antigens while living in the same geographical area and under the same level 
of transmission as the Dogon [42]. In addition, Ubillos et al. recently described that, amongst other 
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factors, nutritional status and hemoglobin concentration significantly affected RTS,S/AS01E vaccine 
immunogenicity in infants and children from two sites in Ghana and Mozambique [43]. 
Multiplex antibody detection platforms have enabled us to test multiple antibody responses 
simultaneously in one sample. This may circumvent the problems described above by including a wider 
panel of antigenic targets to ensure that all those exposed to malaria are detected despite difference 
in parasite and human populations. It also allows for integrated sero-surveillance (i.e. to assess 
different  pathogens [44]) as well as assessment of multiple malarial targets with different kinetics 
which increases the information from one cross-sectional survey [35,45]. 
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Figure 3: Comparison of EIR, SCR and parasite rate measurements from multiple African sites [46–
56]. The seroconversion rate (SCR; using merozoite surface protein 1) has a stronger association with 
transmission (i.e. larger correlation coefficient; R2), as measured by the entomological inoculation rate 
(EIR), compared to the parasite rate. Figure copied from Greenhouse et al. [45].  
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Outstanding issues 
There are some outstanding issues for serological assays that need to be addressed which vary from 
technical (i.e. related to the assay) to analytical (i.e. related to the interpretation of results) and 
operational (i.e. related to the translation of results to operational actions); Figure 4 (adapted from 
Greenhouse et al. [45]). Some of these issues will be discussed below with an emphasis on serological 
metrics using multi-antigenic antibody responses but these do not cover all.  
Firstly, the detection of multiple antibody responses simultaneously makes the assessment of assay 
variability between daily experiments and operators more difficult. The range of immunogenicity 
profiles of antibody responses mean that assay conditions will likely not be ideal for all. In addition, 
positive control hyper-immune sera are unlikely to show robust responses to all the antigens in the 
panel, depending on the number and type of antigens tested [57]. Secondly, to date, most serological 
metrics use antibody responses that are reduced to binary values which results in loss of information. 
The magnitude of the antibody response is an important factor in assessing a population’s exposure 
history as under reduction of transmission, antibody levels will decrease along all ages but some 
individuals, especially adults, will not necessarily revert to a seronegative state (as repeated exposure 
has boosted antibody levels) [58,59]. Arnold et al. re-analysed the Garki project data [58], which was 
collected in an area of high malaria transmission and showed that antibody titres reduced in 0-20 year 
olds following IRS and mass drug administration (MDA), but seroprevalence only reduced among 
children <5 years old [30]. The use of continuous antibody metrics, however, calls for a well-
standardised assay. Thirdly, (continuous or binary) antibody responses to up to 40 or 50 antigens have 
made it difficult to interpret results into actionable responses (e.g. do we intervene in a certain area? 
Is there remaining malaria transmission in this area? Has transmission changed in recent years?). As 
the use of multiplex antibody detection as a tool for epidemiological characterisation is relatively new, 
the interpretation and/or how to reduce information to manageable results is not yet validated. 
Although the hypothesis is that by using ELISA certain individuals who were exposed to malaria but 
did not show an antibody response to the one or two antigen(s) under investigation might have been 
missed, it is unlikely that we need as many as tens to fifty antigens to accurately describe malaria 
transmission patterns. Identifying a subset of antigens (i.e. 3-5) that combined can describe recent, 
intermediate and historical transmission would be advantageous. 
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The ultimate goal: use-case-scenarios for sero-surveillance 
Greenhouse et al. (under review, Gates Open Research) have described five priority use-case-scenarios 
for antibody metrics in sero-surveillance: to document absence of transmission, for stratification of 
risk, to measure the impact of interventions, for decentralised immediate response, and for a P. vivax 
test and treat approach. For most of the use-case-scenarios, it is important that results are readily 
available and easy to interpret for quick turnaround (i.e. a clear framework for analyses). The 
optimisation framework of such an assay, from antigen availability to identification of the most 
informative combinations of responses, to validation of those responses in field trials, and finally, to 
the design of a point-of-care or lab-based antibody detection assay is shown in Figure 4. It should be 
noted that this framework (as well as the work discussed in this thesis) is dependent on variability in 
the production process, quality control, and ultimate availability of antigens which I will not assess in 
this thesis, however an overview of factors associated with antigen selection prior to analytical 
interpretation is shown in Figure 5. 
 
Summary & thesis outline 
The aim of this thesis is to assess the performance of antimalarial antibody metrics for active detection 
in low transmission and pre-elimination settings. Firstly, I will focus on other malaria metrics for active 
detection to identify where antibody metrics would be needed most. It has previously been shown 
that microscopy detects approximately 50% of all infections and these submicroscopic (or: low-
density) infections are more common in adults and at low transmission [24,25]. To date, the 
performance of RDT relative to microscopy and PCR has not been compared in a comprehensive meta-
analysis. Therefore, Chapter 3 will aim to answer what the relationship is between PCR, RDT and 
microscopy prevalence estimates in asymptomatic populations using published and unpublished data 
from cross-sectional surveys in endemic settings. 
Considering the extent of low-density infections at low transmission, adjunct metrics of malaria 
transmission should be investigated. Antibody responses represent past exposure to infection and, in 
combination with age, reflect a population’s transmission history [40,55,60]. Antibody responses with 
relatively short half-lives may help to identify recent transmission patterns after a shorter period of 
time [35]. However, it is currently unknown if low-density infections induce measurable antibody 
responses, in particular to antigens associated with recent exposure. Chapter 4 aims to answer which 
of forty, mainly blood-stage related, antigens induce measurable antibody responses using protein 
microarray and samples from participants who underwent low-density controlled human P. 
falciparum infections.  
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The development of multiplex antibody detection methods, such as protein microarray, has led to a 
vast amount of information across antibodies with different kinetic profiles. However, assay 
standardisation is challenging. Rogier et al. have recently described a multiplex bead assay (MBA) 
protocol which further improves throughput so that results from large-scale malaria surveys can 
directly inform control and elimination policies (Rogier et al., in preparation, Appendix A). In this 
protocol, sample (primary antibody) and anti-human secondary antibody are incubated 
simultaneously to reduce hands-on assay processing time and improve the ease-of-use of the assay. 
Chapter 5 will aim to assess the precision of this recently described MBA protocol for antimalarial 
antibody detection, and will compare results to responses collected on a “conventional” MBA protocol 
(in which sample and anti-human secondary antibody are incubated consecutively with washes in 
between assay steps).  
For certain use-case-scenario of antibody metrics (Figure 4), the design of a standardised, low-cost, 
high-throughput, easy-to-use assay for which results are readily interpretable, would be advantageous 
compared to interpreting results across multiple antibodies. In commercially available ELISAs, antigens 
are pooled to assess antibody responses for past exposure to malaria. These have been applied to 
screen blood products for evidence of malaria exposure prior to transfusion [61–65]. Chapter 6 will 
aim to answer whether antibody measures from commercially available ELISA kits can be used to 
determine recent transmission patterns in an area of low transmission and pre-elimination. 
 
  
60 
 
 
Figure 4: Schematic of optimisation framework of serological metrics and examples of outstanding issues. Adapted from Greenhouse et al. [45] a Factors 
associated with the available antigen panel prior to analytical interpretation are shown in Figure 7. b Use-case-scenarios were described by Greenhouse et al. 
(under review, Gates Open Research). c These are examples of outstanding issues, but it should be noted that this is not a complete list. POC: Point-of-care. 
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Figure 5: Flow-chart of factors that influence antigen selection prior to analytical interpretation. *To 
microtitre plate in ELISA, beads in multiplex bead assays or slides in protein microarrays. 
  
Antigen 
production
• Type of construct design: IVTT, population genetics, genome
sequencing, protein characteristics (e.g. solubility) or homology
with other species
• Expression system
Antigen 
fixation*
• Storage and stability of antigen
• Antigen concentration and batch-to-batch variation
• Selection of positive control pool to assess reactivity to antigen
Assay
• Variation between assay runs and operators (i.e. due to assay
conditions, technician expertise, laboratory conditions, quality and
stability of reagents as well as the selection of the positive control
pool to assess this variation)
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Chapter 2: Objectives 
Objective 
The research projects presented in this thesis had a general objective to assess the performance of 
antimalarial antibody metrics for active detection (i.e. cross-sectional populations) in low transmission 
and pre-elimination settings. 
 
Rationale & specific objectives 
Chapter 3 
Microscopy detects about half of all malaria infections identified by PCR and these submicroscopic, 
low-density infections are more common in adults and at low transmission [1,2]. A recent analysis of 
Demographic and Health Surveys (DHS) data across Africa showed a higher prevalence of malaria 
measured by RDT compared to microscopy in 19 out of 22 surveys [3]. However, this study only 
included children under 5 years old and did not assess the effect of transmission intensity on 
discordance between these diagnostics. A large-scale, pooled analysis simultaneously comparing the 
concordance in prevalence estimates detected by microscopy, PCR and RDTs has not yet been 
performed.  
A meta-analysis using PCR, RDT and microscopy prevalence estimates by geographical clusters sourced 
from literature review and unpublished cross-sectional data was conducted to determine the 
relationship between these estimates. 
Specific objectives 
- To examine the relationship between malaria prevalence measures obtained by PCR, RDT and 
microscopy for the detection of P. falciparum infections in endemic populations 
o To determine the effect of transmission intensity on discordance in prevalence measures 
obtained by RDT compared to PCR 
o To identify explanatory factors for discordance in prevalence estimates obtained by RDT 
compared to microscopy, and RDT compared to PCR, after adjusting for transmission 
intensity 
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Chapter 4 
Antibody responses (IgG) have been suggested as an adjunct measure of malaria transmission as, in 
combination with age data, they can reflect both historical and recent transmission patterns [4–6]. 
They may prove particularly useful at low transmission as they represent cumulative exposure over 
time and thus are less sensitive to seasonal fluctuations in parasite rates and fluctuations in parasite 
density over the course of an infection. However, low-density infections are frequent at low 
transmission [1,2], and it remains  unknown which antigens reliably induce measurable antibody 
responses to allow accurate detection of recent exposure to low-density infections. A powerful model 
to examine this is using controlled human malaria infections (CHMI) in which healthy volunteers are 
infected with the Plasmodium parasite.  
Participant serum samples from eight previously performed CHMI studies were available one day pre-
CHMI as well as one and two to seven months post-CHMI, and were tested for IgG responses using a 
protein microarray with forty antigenic targets, nearly all blood-stage related. 
Specific objectives 
- To identify antigens that induce measurable IgG responses following recent low-density P. 
falciparum infections in previously malaria-naïve CHMI participants 
o To determine if all participants induce measurable IgG responses to any of the forty 
antigenic targets assessed one month and two to seven months after challenge with 
malaria infection 
o To assess the number of antigenic targets needed to detect all participants with 
measurable antibody responses one month and two to seven months after challenge to 
malaria infection 
 
Chapter 5 
Measuring antibody responses to malaria can aid in describing malaria transmission patterns, 
especially at low transmission where infections and cases are infrequent. A pre-requisite to this is a 
standardised assay to compare antibody measures between surveys and populations. A suitable 
platform for this is multiplex bead assays (MBA) for antibody detection, which have recently been 
developed and applied to the malaria research field [7]. MBAs require a fraction of the reagent 
quantities, sample volumes and technician time compared to ELISAs to generate responses to many 
antigens [7,8]. Rogier et al. recently described the OneStep protocol in which sample and anti-human 
IgG are incubated simultaneously, which further increased the throughput of the MBA (Rogier et al., 
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in preparation, Appendix A). The OneStep protocol showed similar sero-prevalence estimates to a 
Stepwise/conventional assay in which sample and anti-human IgG were incubated separately with 
washes in between assay steps. However, the precision of the assay and the comparison of continuous 
antibody measures between protocols has not yet been evaluated.  
Chapter 5 uses data collected in three large-scale malaria transmission surveys in Haiti. A standard of 
Haitian hyperimmune sera was pooled and a 6-point dilution series was included on each plate 
alongside participant samples. Furthermore, a 6-point dilution series of the P. falciparum WHO 
reference standard 10/198 [9] was included on one plate per day. These standard curves were used 
to assess assay precision. Lastly, 804 participant samples were tested on both the OneStep and 
Stepwise MBA protocol to determine the relationship in antibody measurements between these 
protocols. 
Specific objectives 
- To assess the applicability of the high-throughput OneStep MBA protocol for IgG data collection 
for large-scale malaria transmission surveys 
o To determine if the OneStep MBA protocol can be used as a high-throughput tool in 
collecting IgG data for participant samples 
o To assess the precision of the OneStep protocol as determined by repeated measures 
from standard curves of positive control hyperimmune sera included on each plate 
o To determine the relationship between continuous measurements of antibody responses 
between the OneStep and a Stepwise/conventional MBA protocol 
 
Chapter 6 
As previously mentioned, a standardised assay is essential to compare serological results across 
studies and populations. However, there are no standardised assays to measure malaria antibodies 
for epidemiological use. There are several commercially available ELISA assays in which antigens are 
pooled, but these have been developed to screen blood donations for evidence of malaria exposure 
prior to transfusion [10–15]. Some have applied these in an epidemiological context, such as in 
Ethiopia [16]. However, to our knowledge, a comparison of the performance of multiple commercially 
available ELISAs for epidemiological characterisation of malaria transmission has not yet been carried 
out.  
Chapter 6 will firstly discuss the applicability of commercially available ELISA kits for epidemiological 
characterisation of transmission. This consisted of the costs per sample, the amount of serum needed 
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to test a sample, specificity using serum samples from malaria unexposed individuals, and cross-
reactivity using serum samples from Toxoplasma-infected individuals. Furthermore, a composite 
measure of ease-of-use was created based on total incubation time, reagent preparation and other 
practical considerations. Finally, the performance of antimalarial antibody measurements using 
commercially available ELISA kits in describing transmission was assessed by testing samples from 
Praia, Cape Verde (low transmission) and Bataan, the Philippines (pre-elimination). 
Specific objectives 
- To determine if antimalarial antibody measures from commercially available ELISA kits can be 
used to describe transmission patterns in a low transmission and pre-elimination area 
o To assess the cost/sample, amount of serum needed per sample, specificity, cross-
reactivity to Toxoplasma, and ease-of-use of commercially available ELISA kits for 
antimalarial antibody detection 
o To compare antimalarial antibody measures from commercially available ELISA kits with 
(historical) malaria case counts from health facilities in a low transmission and pre-
elimination area 
o To assess the costs/sample, amount of serum needed per sample, specificity, cross-
reactivity to Toxoplasma and ease-of-use of an established research-based ELISA for 
antimalarial antibody detection 
o To compare antimalarial antibody measures from an established research-based ELISA 
with (historical) malaria case counts from health facilities in a low transmission and pre-
elimination area 
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Supplementary Tables 
Table 1 | Logistic regression analyses of explanatory factors for RDT:microscopy discordance. Adjusted for random effects at the country level. 
 Microscopy+  Microscopy- 
RDT-/RDT+ RDT+/RDT- 
RDT-Mic+/ 
RDT+Mic+ 
Crude OR  
(95% CI) 
p Adjusted1 OR 
(95% CI) 
p RDT+Mic-/ 
RDT-Mic- 
Crude OR  
(95% CI) 
p Adjusted1 OR 
(95% CI) 
p 
Age (years) 
- ≤15  
- >15 
 
4698/23940 
33/116 
 
1 
1.63 (0.96-2.75) 
 
 
0.069 
 
1 
1.16 (0.66-2.05) 
 
 
0.598 
 
10493/81372 
105/1229 
 
1 
0.63 (0.31-1.29) 
 
 
0.205 
 
1 
1.24 (0.73-2.09) 
 
 
0.426 
Gender 
- Female 
- Male 
 
2488/12910 
2515/12991 
 
1 
1.01 (0.95-1.06) 
 
 
0.837 
 
1 
1.01 (0.95-1.06) 
 
 
0.845 
 
5627/43278 
5510/42416 
 
1 
1.00 (0.95-1.05) 
 
 
0.969 
 
1 
0.99 (0.95-1.04) 
 
 
0.804 
Febrile2 
- No 
- Yes 
 
1995/9307 
738/5312 
 
1 
0.59 (0.39-0.89) 
 
 
0.011 
 
1 
0.55 (0.40-0.76) 
 
 
<0.001 
 
4051/36541 
2907/13901 
 
1 
2.12 (1.58-2.85) 
 
 
<0.001 
 
1 
1.84 (1.51-2.24) 
 
 
<0.001 
RDT brand 
- Paracheck 
- SD-Bioline 
- FR 
- Carestart 
- ICT 
 
2376/12874 
2009/9804 
484/2508 
95/583 
14/29 
 
1 
1.14 (0.64-2.04) 
1.06 (0.42-2.65) 
0.86 (0.39-1.90) 
4.12 (0.83-20.41) 
 
 
0.663 
0.907 
0.710 
0.082 
 
1 
0.97 (0.52-1.81) 
1.03 (0.39-2.68) 
0.50 (0.21-1.20) 
2.34 (0.42-13.08) 
 
 
0.924 
0.960 
0.122 
0.334 
 
4510/34316 
5175/34843 
1175/8228 
172/6730 
18/795 
 
1 
1.15 (0.44-3.00) 
1.10 (0.24-5.01) 
0.17 (0.08-0.38) 
0.15 (0.05-0.47) 
 
 
0.771 
0.901 
<0.001 
0.001 
 
1 
1.41 (0.81-2.43) 
0.29 (0.57-2.94) 
0.43 (0.28-0.65) 
0.47 (0.18-1.24) 
 
 
0.224 
0.543 
<0.001 
0.127 
ITN use 
- No 
- Yes 
 
2408/13531 
2526/11964 
 
1 
1.24 (0.98-1.55) 
 
 
0.068 
 
1 
1.26 (1.00-1.59) 
 
 
0.053 
 
5658/37615 
5369/44611 
 
1 
0.77 (0.64-0.93) 
 
 
0.006 
 
1 
0.84 (0.73-0.97) 
 
 
0.019 
Antimalarial3 
- No 
- Yes 
 
726/4964 
256/1917 
 
1 
0.90 (0.67-1.20) 
 
 
0.477 
 
1 
0.90 (0.67-1.20) 
 
 
0.477 
 
2571/24861 
1212/4275 
 
1 
3.43 (2.13-5.51) 
 
 
<0.001 
 
1 
1.71 (1.16-2.51) 
 
 
0.006 
Year of study  1.12 (0.96-1.31) 0.140 1.08 (0.93-1.24) 0.306  0.95 (0.73-1.23) 0.683 1.06 (0.93-1.20) 0.400 
Cluster 
microscopy 
prevalence 
 
 
 
 
0.99 (0.98-1.00) 
 
 
0.004 
 
 
NA 
 
 
NA 
 
 
 
 
 
1.05 (1.04-1.06) 
 
 
<0.001 
 
 
NA 
 
 
NA 
RDT: rapid diagnostic test, OR: odds ratio, CI: confidence interval, p: p-value, FR: First Response, ITN: insecticide treated net.1Adjusted for cluster microscopy prevalence. 
2Reported fever (DHS) or recorded fever with study-specific cut-off. 3Self-reported; in the previous 14 days. 
 
 
 
 
Table 2 | Logistic regression analyses of explanatory factors for RDT:PCR discordance. Adjusted for random effects at the study level. 
 PCR+ PCR- 
RDT-/RDT+ RDT+/RDT- 
RDT-PCR+/ 
RDT+PCR+ 
Crude OR  
(95% CI) 
p Adjusted1 OR 
(95% CI) 
p RDT+PCR-/ 
RDT-PCR- 
Crude OR  
(95% CI) 
p Adjusted1 OR 
(95% CI) 
p 
Age (years) 
- ≤5  
- 6-15 
- >15 
 
370/714 
380/732 
328/397 
 
1 
1.00 (0.70-1.43) 
4.42 (3.24-6.04) 
 
 
0.984 
<0.001 
 
1 
0.97 (0.68-1.38) 
5.04 (4.14-6.13) 
 
 
0.852 
<0.001 
 
153/6369 
190/5407 
109/3313 
 
1 
1.48 (1.29-1.70) 
1.38 (0.60-3.18) 
 
 
<0.001 
0.447 
 
1 
1.53 (1.28-1.82) 
1.00 (0.64-1.58) 
 
 
<0.001 
0.990 
Gender 
- Female 
- Male 
 
593/970 
482/870 
 
1 
0.79 (0.55-1.12) 
 
 
0.191 
 
1 
0.73 (0.52-1.03) 
 
 
0.071 
 
265/7562 
187/6647 
 
1 
0.80 (0.59-1.07) 
 
 
0.132 
 
1 
0.88 (0.71-1.08) 
 
 
0.226 
Febrile2 
- No 
- Yes 
 
412/667 
37/206 
 
1 
0.14 (0.06-0.32) 
 
 
<0.001 
 
1 
0.14 (0.06-0.34) 
 
 
<0.001 
 
190/2786 
81/308 
 
1 
4.88 (2.31-10.28) 
 
 
<0.001 
 
1 
4.86 (2.29-10.30) 
 
 
<0.001 
PCR method 
- nPCR 
- qPCR 
 
845/1525 
245/330 
 
1 
2.32 (1.44-3.74) 
 
 
0.001 
 
1 
1.92 (0.98-3.74) 
 
 
0.056 
 
384/7768 
68/7334 
 
1 
0.18 (0.06-0.59) 
 
 
0.005 
 
1 
0.34 (0.10-1.18) 
 
 
0.090 
RDT brand 
- Paracheck 
- FR 
- Carestart 
- ICT 
- SD-Bioline 
 
393/575 
230/522 
207/400 
52/70 
62/86 
 
1 
0.36 (0.14-0.93) 
0.50 (0.23-1.05) 
1.34 (0.30-5.93) 
1.20 (0.56-2.54) 
 
 
0.034 
0.068 
0.702 
0.640 
 
1 
0.48 (0.28-0.81) 
0.65 (0.49-0.86) 
0.90 (0.17-4.82) 
2.07 (1.25-3.43) 
 
 
0.924 
0.960 
0.122 
0.334 
 
169/4275 
131/1500 
74/1607 
15/747 
12/140 
 
1 
2.32 (0.62-8.74) 
1.17 (0.25-5.46) 
0.50 (0.10-2.47) 
2.28 (0.49-10.60) 
 
 
0.212 
0.839 
0.394 
0.294 
 
1 
1.43 (0.55-3.68) 
0.86 (0.34-2.16) 
0.59 (0.14-2.60) 
0.82 (0.46-1.49) 
 
 
0.460 
0.742 
0.489 
0.526 
Year of survey 1855 0.68 (0.54-0.85) 0.001 0.77 (0.60-0.99) 0.044 1502 1.13 (0.71-1.80) 0.595 1.08 (0.78-1.48) 0.654 
Cluster PCR 
prevalence 
 
1855 
 
0.96 (0.93-0.99) 
 
0.014 
 
NA 
 
NA 
 
1502 
 
1.06 (1.03-1.09) 
 
<0.001 
 
NA 
 
NA 
PCR: polymerase chain reaction, RDT: rapid diagnostic test, OR: odds ratio, CI: confidence interval, p: p-value, FR: First Response, nPCR: nested PCR, qPCR: quantitative PCR. 
1Adjusted for cluster PCR prevalence. 2Recorded temperature ≥37.5°C; collected in 3 out of 9 studies. 
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Supplementary Tables 
 
Supplementary Table 1: Controlled human malaria infection trials included in the study. Samples 
from participants across eight controlled human malaria infection trials were analysed in the current 
study.  
Study Year NCT number Ethical approval CCMO Reference 
1 2011 NCT01236612 NL34273.091.10 [24] 
2 2011 NCT01218893 NL33904.091.10 [25] 
3 2012 NCT01422954 NL 37563.058.11 [26] 
4 2012 NCT01728701 NL39541.091.12 [9] 
5 2015 NCT02080026 NL48301.091.14 - 
6 2015 NCT02098590 NL48732.091.14 [23] 
7 2015 NCT02098590 NL48732.091.14 [23] 
8 2016 NCT02836002 NL56659.091.16 [27] 
NCT: National Clinical Trial. CCMO: Central Committee on Research Involving Human Subjects. 
  
 
 
Supplementary Table 2: Characteristics of antigens included on the protein microarray. 
Order Gene ID Acronym Description Location Expression 
tag 
Strain Reference 
1 PF3D7_1001100_1_ACBP
1 
ACBP1 exported protein, unknown 
function: Phista  
iRBC GST 3D7 Helb et al (PMID: 
26216993); Tetteh 
unpublished 
2 PF3D7_0731600 ACS5 Ag 4 Acyl CoA Synthase. Antigen 
4 (fragment 4) 
iRBC GST 3D7 Helb et al (PMID: 
26216993); Tetteh 
unpublished 
3 PF3D7_0304600 CSP Most predominant and 
antigenic protein on 
sporozoite surface. 
Component of RTS,S vaccine 
Sporozoite n/a 3D7 Kastenmuller et al 
(PMID: 23275094)  
4 PF3D7_1301600 EBA140 RIII-V erythrocyte binding antigen 
140; involved in invasion  
Apical organelles, 
micronemes 
GST 3D7 Richards et al 
(PMID: 20843207) 
5 PF3D7_0731500  EBA175RII_F2 erythrocyte binding antigen 
175; RBC binding region via 
glycophorin A 
Apical tip GST 3D7 Richards et al 
(PMID: 20843207) 
6 PF3D7_1101800 EPF1v2 Exported protein; PV to 
iRBC surface 
iRBC, maurer's 
cleft 
GST 3D7 Helb et al (PMID: 
26216993); Tetteh 
unpublished 
7 PF3D7_0423700 Etramp 4 
antigen 1 
Early transcribed membrane 
antigen. Integral PVM 
protein. N-terminal  
iRBC, PVM GST 3D7 Helb et al (PMID: 
26216993); Tetteh 
unpublished 
8 PF3D7_0423700 Etramp 4 
antigen 2 
Early transcribed membrane 
antigen. Integral PVM 
protein. C-terminal 
iRBC, PVM GST 3D7 Helb et al (PMID: 
26216993); Tetteh 
unpublished 
9 PF3D7_0532100 Etramp 5 Ag 1 Early transcribed membrane 
antigen. Integral PVM 
protein. 
iRBC, PVM GST 3D7 Spielmann et al 
(PMID: 
12686607); Tetteh 
K unpublished 
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Order Gene ID Acronym Description Location Expression 
tag 
Strain Reference 
10 PF3D7_0532100 Etramp 5 Ag 2 Early transcribed membrane 
antigen. Integral PVM 
protein. 
iRBC, PVM GST 3D7 Helb et al (PMID: 
26216993); Tetteh 
unpublished 
11 PF3D7_0402400 GEXP18 Gametocyte exported 
protein 18. Unknown 
function. 
iRBC/Gametocyt
e 
GST 3D7 Helb et al (PMID: 
26216993); Tetteh 
unpublished 
12 PF3D7_1035300 GLURP R0 Glutamate rich protein R0 Merozoite 
Surface 
n/a F32 Theisen et al 
(PMID: 7719909) 
13 PF3D7_1035300 GLURP R2 Glutamate rich protein R2 Merozoite 
Surface 
n/a F32 Theisen et al 
(PMID: 7719909) 
14 PF3D7_0501100.1 HSP40 Ag 1 Heat shock protein 40 iRBC GST 3D7 Helb et al (PMID: 
26216993); Tetteh 
unpublished 
15 PF3D7_0501100.1 HSP40 Ag 3 Heat shock protein 40 iRBC GST 3D7 Helb et al (PMID: 
26216993); Tetteh 
unpublished 
16 PF3D7_0207000 MSP4 Merozoite surface protein.  Merozoite 
surface 
GST D10 Marshall et al 
(PMID: 9353020) 
17 PF3D7_0206900 MSP5 Merozoite surface protein.  Merozoite 
surface 
GST 3D7 Marshall et al 
(PMID: 9719507) 
18 PF3D7_1035700 MSP DBL1 N-
term 
MSPDBL1 N-terminal Merozoite 
surface 
GST 3D7 Tetteh et al 
(PMID: 23897617)  
19 PF3D7_0930300 MSP1 bk2 
MAD20 Rep 
MSP1 block 2 MAD20 allele 
(MAD20 type) repeat region 
only.  
Merozoite 
surface 
GST MAD20 Polley et al (PMID: 
12654798) 
20 PF3D7_0930300 MSP1 bk2 
MAD20 full 
MSP1 block 2 MAD20 allele 
(MAD20 type) full-length 
region (repeat and type-
specific flanking region). 
  
Merozoite 
surface 
GST MAD20 Kimbi et al (PMID: 
15109551) 
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Order Gene ID Acronym Description Location Expression 
tag 
Strain Reference 
21 PF3D7_0930300 MSP1 bk2 Well 
Rep 
MSP1 block 2 Wellcome 
allele (MAD20 type) full 
block 2 region, repeat only, 
type specific flanking region 
removed 
Merozoite 
surface 
GST Wellcom
e 
Polley et al (PMID: 
12654798) 
22 PF3D7_0930300 MSP1 block 2 
Palo Alto 
Repeat 
MSP1 block 2 Palo Alto 
allele K1 type) full block 2 
region, repeat only, type 
specific flanking region 
removed 
Merozoite 
surface 
GST Palo Alto Polley et al (PMID: 
12654798) 
23 PF3D7_0930300 MSP1 block 2 
Palo Alto full #6 
MSP1 block 2 Palo Alto 
allele K1 type) full block 2 
region, includes type 
specific flanking region 
Merozoite 
surface 
GST Palo Alto Polley et al (PMID: 
12654798) 
24 PF3D7_0930300 MSP1 block 2 
R033 
MSP1 block 2 R033 allele 
(R033 type) full-length. 
Merozoite 
surface 
GST RO33 Kimbi et al (PMID: 
15109551) 
25 PF3D7_0930300 MSP1 block 2 
Well full 
MSP1 block 2 Wellcome 
allele (MAD20 type) full 
block 2 region, includes type 
specific flanking region 
Merozoite 
surface 
GST Wellcom
e 
Kimbi et al (PMID: 
15109551) 
26 PF3D7_0206800 MSP2 CH150/9 CH150/9 allele of MSP2. 
Full-length. 
Merozoite 
surface 
GST CH150/9 Polley et al (PMID: 
16111789) 
27 PF3D7_0206800 MSP2 Dd2 Dd2 allele of MSP2. Full-
length. 
Merozoite 
surface 
GST DD2 Taylor et al (PMID: 
7591074) 
28 PF3D7_1035400 MSP3-3D7 MSP3 3D7 allele Merozoite 
surface 
MBP 3D7 Polley et al (PMID: 
17191173) 
29 PF3D7_1035700 PF10_0348 C-
term 
MSPDBL1 C-terminal Merozoite 
surface 
GST 3D7 Tetteh et al 
(PMID: 23897617) 
30 PF3D7_1036300 PF10_0355 C-
term 
Duplicate antigen. MSPDBL2 
C-terminal 
Merozoite 
surface  
GST 3D7 Tetteh et al 
(PMID: 23897617) 
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Order Gene ID Acronym Description Location Expression 
tag 
Strain Reference 
31 Pf3D7_0402000 Phista_040200
0 
exported protein, unknown 
function: Phista  
iRBC cytoplasm GST 3D7 Helb et al (PMID: 
26216993); Tetteh 
unpublished 
32 Pf3D7_0424900 Phista_042490
0 
exported protein, unknown 
function: Phista  
iRBC cytoplasm GST 3D7 Helb et al (PMID: 
26216993); Tetteh 
unpublished 
33 Pf3D7_0425400 Phista_042540
0 
exported protein, unknown 
function: Phista  
iRBC cytoplasm GST 3D7 Helb et al (PMID: 
26216993); Tetteh 
unpublished 
34 Pf3D7_0601700 Phista_060170
0 
exported protein, unknown 
function: Phista  
iRBC cytoplasm GST 3D7 Helb et al (PMID: 
26216993); Tetteh 
unpublished 
35 PF3D7_1133400 AMA1 Apical membrane antigen 1 micronemes His FVO Collins et al 
(PMID: 17192270) 
36 PF3D7_0930300 MSP1-19 19kDa fragment of MSP1 
molecule.  
Merozoite 
surface 
GST Wellcom
e 
Burghaus and 
Holder (PMID: 
8078519)  
37 PF3D7_1021800 PfSEA-1 Schizont egress antigen. iRBC GST 3D7 Raj et al (PMID: 
24855263); Tetteh 
K unpublished 
38 PF3D7_0936300 REX 3 Ring exported protein,  iRBC GST 3D7 Helb et al (PMID: 
26216993); Tetteh 
unpublished 
39 PF3D7_0424100 Rh5 Receptor for human protein 
Basigin.  
Apical tip C-tag 3D7 Jin et al (PMID: 
30131879); 
Crosnier et al 
(PMID: 
22080952); Tetteh 
K unpublished 
  
105 
 
Order Gene ID Acronym Description Location Expression 
tag 
Strain Reference 
40 PF3D7_0501300 SBP1 skeleton-binding protein; 
essential for translocation 
of PfEMP1 to iRBS surface 
via Maurer's cleft. 
iRBC GST 3D7 Gruring et al 
(PMID: 
21266965); Tetteh 
K unpublished 
GPI: Glycosylphosphatidylinisotol; PVM: parasitophorous vacuolar membrane; iRBC = infected red blood cell.
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Supplementary Figures 
 
 
 
 
Supplementary Figure 1: Duplicate median fluorescence intensity measures from repeated spots on 
the protein micro-array. Paired measurements across all the samples tested are shown; duplicate 
measures were averaged for analyses. The grey line represents the line of equality. Pearson’s ρ=0.99, 
p<0.001. 
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Supplementary Figure 2: Antibody responses over categories of cumulative parasite density thirty 
days post-challenge. Cumulative parasite density is expressed as the log-transformed area under the 
curve for parasite density versus time until, and including the day of treatment. Tertiles were used to 
categorise low, medium and high. Antibody responses are expressed as log-transformed median 
fluorescence intensity corrected for background reactivity. Red dashed lines represent thresholds of 
seropositivity using the mean plus two standard deviations of pre-challenge responses across 45 
participants. For Etramp 4 Ag 2, the outlier at baseline was removed for the threshold calculation; the 
blue dashed line represents the threshold if the outlier at baseline was included. 
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Additional File: Comparison of median fluorescence intensity 
measures recorded by protein microarray and multiplex bead assay 
To compare median fluorescence intensity (MFI) measures for antimalarial IgG recorded by protein 
microarray and suspension bead array (SBA, synonym for MBA), samples from controlled human 
malaria infection (CHMI) participants were tested on both platforms. Samples were available at one 
day pre-CHMI, thirty days post challenge or 2-7 months post-CHMI. The thirty days post-CHMI time 
point was chosen as the highest antibody responses were recorded at this time point by protein 
microarray (Chapter 4, page 93). 
Methods 
The assay protocol for protein microarray was performed as described in this chapter (Chapter 4, page 
90). For SBA this was performed as described by Wu et al. (in press, Wellcome Open Research). Serum 
samples were tested for antimalarial IgG at a serum concentration of 1:200 for both platforms. All the 
antigens that were included on the protein microarray and optimised for use on the SBA platform at 
the time were analysed (8 out of 40 antigens analysed on the protein microarray in Chapter 4). For 
antigen abbreviations see Supplementary Table 2 (Chapter 4). All statistical analyses were performed 
in STATA 14. 
Results 
Figure 1 shows paired MFI measurements as recorded by protein microarray and SBA in 45 CHMI 
participant samples thirty days post-CHMI. Generally, absolute values for MFI are higher on the SBA 
compared to protein microarray, except for CSP and SEA-1. Strong correlation (i.e. correlation 
coefficient >0.7) was seen in recorded MFI values on both platforms (Table 1), except for AMA-1 which 
showed moderate linear correlation (Pearson’s correlation coefficient 0.539, p<0.001). In addition, 
both CSP and AMA-1 showed moderate rank correlation (Spearman’s correlation coefficient 0.647 and 
0.540, respectively). 
Conclusion 
A strong correlation was recorded between MFI measurements recorded by protein microarray and 
SBA in CHMI participants thirty days post-CHMI for six out of eight antigens analysed (Table 1). 
Antibody responses in CHMI participants are likely to be lower than those recorded following naturally 
acquired infections as parasite densities remain low (i.e. peak parasite densities remained below 200 
parasites/µl for all participants). Therefore, antibody responses for some antigens remained low (e.g. 
AMA-1) thus making it difficult to draw conclusions on the agreement between platforms for these 
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antigenic targets. Discordances in MFI measures between platforms may have been caused by 
variations in immunogenicity of antigen batches, differences in antigen concentrations, improved 
conservation of the conformational structure of antigens on beads (SBA) compared to nitrocellulose 
microscope slides (protein microarray), or other assay-specific factors (i.e. the fluidics of antigen-
antibody interaction in SBA compared to fixation of antigen to slides in protein microarray). 
Future work should focus on comparing MFI measurements between protein microarray and 
SBA/MBA using samples with a wider range of antibody responses as the current analyses only 
included samples from individuals who harboured low-density infections. Therefore, the current 
analyses gave limited information for those antigenic targets that this population did not show a 
response to (e.g. AMA-1 which showed the lowest Spearman correlation coefficient: 0.540). 
Technically the MBA platform can be assumed the gold standard in this comparison as antigen 
concentrations for bead couplings are optimised through titration against a standard, whereas protein 
microarray uses a set amount of antigen printed on the slide (i.e.100 µg/µl). Moreover, as mentioned, 
the conformational structure of antigens is more likely to be conserved in SBA and the fluidics of the 
SBA assay allows efficient interaction of antigens and antibodies.   
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Figure 1: Comparison of median fluorescence intensity (MFI) measured by protein microarray (array) and suspension bead array (SBA; i.e. multiplex bead 
assay) in controlled human malaria infection participants thirty days post-challenge. Samples were available for 45 participants. Participant samples are 
shown in grey dots, while the red marker in the left top plot represents a pool of hyperimmune Tanzanian sera. For antigen abbreviations, see Supplementary 
Table 2 (Chapter 4). 
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Table 1: Correlation coefficients for paired median fluorescence intensity measurements recorded 
by protein microarray and suspension bead array (i.e. multiplex bead assay) in samples from 
controlled human malaria infection participants thirty days post-challenge. Samples were available 
for 45 participants.  
Antigen Pearson’s 
correlation 
coefficient 
p-value Spearman’s 
correlation 
coefficient 
p-value 
GLURP-R2 0.899 <0.001 0.925 <0.001 
CSP 0.889 <0.001 0.647 <0.001 
EBA140 RIII-V 0.884 <0.001 0.892 <0.001 
Etramp 4 Ag 2 0.817 <0.001 0.725 <0.001 
Etramp 5 Ag 1 0.855 <0.001 0.872 <0.001 
AMA-1 0.539 <0.001 0.540 <0.001 
MSP-119 0.822 <0.001 0.834 <0.001 
SEA-1 0.825 <0.001 0.814 <0.001 
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Abstract 
Background: 
Measuring antibody responses to malaria can aid in describing malaria transmission patterns 
especially at low transmission where infections and cases are infrequent. A pre-requisite to this is a 
standardised assay to adequately compare antibody measures between surveys and populations. 
Here we describe the in-country application and retrospective quality control of a multiplex bead assay 
(MBA) used to collect antibody measurement in large-scale malaria transmission surveys in Haiti.  
Results: 
Antibody measurements (IgG) to twenty-one recombinant antigens and peptides were collected for 
32,758 participant samples in eighteen weeks using a recently described One-Step protocol (in which 
test sample and anti-human IgG are incubated simultaneously). Standard curves of a pool of 
hyperimmune sera from Haitians as well as a Plasmodium falciparum WHO reference standard 
(10/198) were tested with samples. 5-parameter logistic regression was used to fit the sigmoidal 
relationship between dilution points of hyperimmune sera pools and recorded antibody measures. 
Inspection of the median and interquartile range (IQR) for the y-inflection point of standard curves 
was used to determine assay precision within and between surveys. Median and IQRs were similar for 
Survey 1 and Survey 2 for most antigens, while the length of the IQR for y-inflection points increased 
for some antigens in Survey 3. The sigmoidal relationship between paired measurements of 804 
samples on the One-Step protocol and a Stepwise protocol (in which sample and anti-human IgG were 
incubated separately with washes in between assay steps) was used to transform One-Step responses 
to Stepwise responses for all survey samples per antigen. The performance of this transformation was 
confirmed by the strong correlation of transformed responses compared to Stepwise responses 
(Pearson’s correlation coefficients ranged from 0.68 to 0.95 depending on the antigen). 
Conclusion: 
This study described the successful in-country application of the MBA with high throughput and 
acceptable inter-plate variability in Haiti. The highly efficient collection of antibody responses (IgG) 
allows for rapid assessment of the exposure history of populations which can directly inform control 
and elimination policies. 
Key words: Antibody detection, multiplex bead assay, Luminex, sero-surveillance, sero-epidemiology.  
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Background 
Measurement of antibody responses to malaria at the population-level can describe recent and 
historical transmission patterns [1–4] and  are informative for malaria research and control policies 
[5–7]. Antibodies can be measured by a variety of techniques including the enzyme-linked 
immunosorbent assay (ELISA) and multiplex bead assays (MBA). The latter allows the simultaneous 
detection of antibodies to multiple antigenic  targets and have first been described for Plasmodium  in 
2006 [8]. Since then numerous assay optimisation and implementation studies [9–17] as well as 
epidemiological application studies [18–21] have been published.  
 
Whilst MBA’s have the advantage of reduced need of reagent quantities, sample volume and 
technician time compared to the ELISA in generating responses to many antigens simultaneously [8,9], 
the multiplex nature is not without technical challenges. All assays will require standards to assess 
variability across runs or batches, and to compare research studies. With a broad panel of antigens in 
the MBA it is potentially difficult to find standards for all targets in the panel. Recently, standard curves 
of known concentrations of total human IgG have been suggested which would enable standardisation 
[13]. However, these did not show sufficient reproducibility between operators. Moreover, these do 
not allow for the assessment of antigen-specific responses which are important for quality control in 
assessing the stability of antigens. Pools of hyperimmune sera are commonly used to identify the 
dynamic range of responses to antigen panels.  Recently, a reference Plasmodium falciparum (Pf) 
WHO standard lyophilised plasma standard has been produced  [22],  and applied in a MBA against a 
panel of 40 malarial and non-malarial antigens [15]. 
 
Previous studies on the application and validation of the MBA have shown its correlation with ELISA 
[8,10,12,17,23], the stability and reproducibility of coupled beads [10,12,16], the use of Ig subclasses 
[15] and IgG isotypes [11,15] as well as mono- vs. multiplex results [10,12,15–17]. Although intra- and 
inter-assay variability have been discussed [10,13,14,16,24] as well as analytical methodologies to 
determine inter-assay variability [25,26], few have formally assessed this on a large-scale (studies of 
several thousand samples over time) [16]. Rogier et al. recently described a One-Step MBA protocol 
in which sample and secondary are incubated simultaneously which further increases the ease-of-use 
and throughput of the MBA (Rogier et al., in prep). Here, we discuss the application and retrospective 
quality control process of the One-Step MBA protocol for antimalarial antibody (IgG) detection in 
large-scale malaria transmission surveys in Haiti. 
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Methods 
Study population 
Three cross-sectional surveys were conducted: two in the Artibonite valley, central Haiti (Survey 1 in 
May-Jun 2017 and Survey 2 in Jul-Sep 2017 with a two-week pause due to hurricanes) and one in 
Grand’Anse, south-western Haiti (Survey 3 in Nov-Dec 2017). Survey 1 included 6,006 participants, 
Survey 2 21,891 and Survey 3 5,034. In the former two surveys finger-prick blood was collected in 
microtubes and spotted on Whatmann 903 cards at the end of the day using pipettes (60 µl per spot), 
whereas in the latter blood was spotted directly onto the Whatmann 903 cards at point-of-contact. In 
all surveys, cards were dried overnight and packed the next day with silica gel. Dried blood spots (DBS) 
were kept at room temperature and were transported to the Laboratoire National de Sante Publique 
(LNSP) in Port-au-Prince once per week where they were stored at 4°C until processed. Participants 
were also tested with a SD-Bioline HRP2 RDT and treated according to national guidelines if positive. 
 
Antigen coupling to beads 
Antigens were covalently coupled to unique bead regions as previously described by Rogier et al. [19]. 
Most of the antigen-bead sets were coupled in one batch at the start of the surveys to minimise batch-
to-batch variation of antigens and bead set couplings. In addition to the malarial antigen panel, 
glutathione S-transferase (GST) protein was included to correct for background reactivity as 
participants that show high (specific or non-specific) GST responses may react to the GST-tag of 
malarial antigens following protein production. TT was included to act as an internal positive control 
as vaccinated participants as well as the negative UK control pool (see below) should show responses 
to this target. Antigen characteristics and details on antigen-bead coupling are depicted in Table 1. 
 
Assay standards 
Hyperimmune positive control pools 
A Haitian positive serum control pool (HP) was created using country-wide, routinely collected 
samples from RDT positive individuals. Blood spots from participants with high responses to a range 
of Pf antigens were combined (n=63) and eluted to a standard at dilution of 1:100. A 6-point titration 
standard curve of 1 in 5 dilutions starting at 1:100 was created in bulk, stored at 4°C and used on each 
test plate. The WHO Pf standard 10/198 [22] was eluted in 1 ml of dH20 (1:5 serum concentration, 
100 units) and subsequently in 10 ml of buffer B (phosphate-buffered saline (PBS) containing 0.5% 
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BSA, 0.05% Tween 20, 0.02% sodium azide, 0.5% polyvinyl alcohol, 0.8% polyvinylpyrrolidone and 0.5% 
w/v E. coli extract).  As with the Haitian pool, a 6-point, 1 in 5 titration standard curve starting at 1:50 
was created in bulk, stored at 4°C but run on only one test plate per day. 
 
Unexposed, negative control pool and blanks 
A pool of 10 serum samples from unexposed individuals from the UK was included on all the plates in 
Survey 1 and the first 150 plates in Survey 2 at a final serum concentration of 1:200. This pool was not 
included on plates in Survey 3. In addition, two blanks (buffer B) were run on each plate. 
 
Multiplex bead assay 
All samples were processed for multiplex antibody (IgG) detection using a One-Step protocol as 
previously described by Rogier et al. (Rogier et al., in prep). Briefly, one 3 mm spot was cut from the 
centre of a DBS and eluted overnight in 173µl of buffer B. Samples were kept at 4°C and tested within 
three weeks. Bead mixture was prepared by adding 6µl per bead region (250,000 beads/antigen/plate) 
in 5 ml of buffer A (PBS containing 0.5% BSA, 0.05% Tween-20, 0.02% sodium azide) for each plate. 
Bead mixture was mixed using an electronic pipette and 50µl was added to each well of a 96-well plate 
(Bio-Rad, Hercules, CA). Plates were placed on handheld magnetic separators (Luminex Corp) and 
washed three times with wash buffer (PBS containing 0.05% Tween-20). After removing plates from 
the separator, 50µl of anti-human secondary mixture in buffer A (1:500 biotinylated anti-human IgG, 
Southern Biotech; 1:1250 biotinylated anti-human IgG4, Southern Biotech; and 1:200 Streptavidin 
conjugated to phycoerythrin, Invitrogen, Waltham, MA) was added to each well, followed by 50µl of 
eluted samples resulting in a final serum concentration of 1:200. Plates were incubated on a shaker 
overnight at 600 rpm. The next day, plates were washed five times and 100µl of PBS was added. Plates 
were kept on the shaker for a minimum of 30 minutes until they were read with the MagPix with Bio-
Plex Manager™ MP software with a target of 20 beads/antigen/well. Median fluorescence intensity 
(MFI) was recorded for each sample and corrected for background reactivity by subtracting blank 
(buffer B only) responses by antigen (MFI corrected for background, hereafter: MFI). Results were 
exported to Excel workbooks per plate. 
 
In addition, 804 samples from survey 1 were run using a Standard (hereafter: Stepwise) protocol in 
which, after the bead mixture wash, beads are incubated with sample for 1.5 hours (final serum 
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concentration of 1:100), secondary for 1 hour and buffer A for 0.5 hour (Rogier et al. 2018, in prep). 
Three washes were done in between each assay step. After the final wash, 100µl of PBS was added 
and plates were read as in the One-Step protocol. 
 
Statistical analyses 
Quality control 
All statistical analyses were performed in R Studio version 3.3.3 [27]. Participants with GST MFI levels 
above the arbitrary threshold of 1000 were excluded from further analyses. All MFI values were log 
transformed (base 10) with MFI values smaller than background responses replaced with the mean 
background values for all antigens (i.e. MFI of 8.45, standard deviation: 2.36). The value of the third 
point of the standard HP curve of each plate was plotted in Levey-Jenning charts. Plates that fell 
outside of the mean +/- 2 standard deviations (SD) for two out of three highly immunogenic antigens 
(GLURP-R2, AMA-1 and MSP1-19) were repeated [16]. Logistic regression curves were fitted to 
standard curve values per plate using the nplr package in R Studio [28]. This function compares 2 to 5 
parameter logistic regression fits and selects the fit with the smallest sum of squared errors. Logistic 
regression was only fitted if no more than one value of the standard curve was missing and at least 
one of the recorded MFI values was > 4.61 (i.e. MFI 100 before log-transformation). MFI values were 
first converted to proportions using the minimum and maximum MFI values for all standard curves 
across all antigens (2.07 and 11.17 respectively). The 5-parameter logistic regression is given below: 
𝑦 =  𝐵 +
𝑇 − 𝐵
[1 + 10(𝑏∗(𝑥𝑚𝑖𝑑−𝑥))]𝑠
 
B and T are the bottom and top asymptotes, b and xmid are the Hill slope and the x-coordinate at the 
inflexion point and s is an asymmetry coefficient. In 4-parameter logistic regression, the s parameter 
is forced to be 1, while 3- or 2-parameter logistic regression force B and T to be 0 and 1, respectively. 
Curve parameters were recorded for each plate as well as a sequence of 200 predicted MFI values 
across standard curve concentrations to represent the fitted curves. 
 
Transformation of antibody responses between the One-Step and Stepwise protocol 
The sigmoidal relationship between paired log-transformed MFI measurements from 804 samples on 
the One-Step and Stepwise MBA protocols (Rogier et al. 2018, in prep) was also fitted using the nplr 
package. The fit from these models was then validated by transforming data collected on the One-
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Step protocol to Step-wise responses and investigating transformed responses compared to Step-wise 
responses. Hereafter, recorded antibody response data from all survey samples were transformed for 
each antigen using these fits. Samples that fell below the bottom asymptote or over the upper 
asymptote, were replaced by the lowest and highest values that the model could estimate. 
 
Results 
High throughput 
Nearly all collected survey samples were processed at the laboratory with minor differences due to 
data management issues or loss of DBS between field collection and laboratory assessment: 99.2% 
(5956/6006) for Survey 1; 99.6% (21,801 /21,891) for Survey 2; and 99.3% (5001/5034) for Survey 3 
(Table 2). These samples were processed in 71 plates over five weeks for Survey 1; 257 plates over 
nine weeks for Survey 2; and 59 plates over four weeks for Survey 3. Together these represent 32,758 
participant samples in eighteen weeks. After removal of high responses to GST for participants with a 
GST reading available (i.e. loss due to well-specific errors such as low bead counts) 5,898 samples were 
available in Survey 1 (99.0% of those received at the laboratory); 21,234 samples in Survey 2 (97.4%); 
and 4,967 samples in Survey 3 (99.3%). IgG antibody responses were successfully collected for all these 
participants across 21 antigens (17 P. falciparum antigens, 2 non-P. falciparum antigens and 2 non-
malarial antigens), apart from minor loss of observations due to well-specific errors: 455 (0.07%), 
which resulted in 673,624 unique observations (Table 2). 
 
Robust responses in both positive control standards 
The highest concentrations of both the HP and the 10/198 positive control standard curves showed 
robust IgG responses for nearly all of the included Pf antigens (Figure 1). Generally higher median 
responses were seen in the 10/198 standard, except for LSA-1 and SBP-1, presumably due in part to 
the higher serum concentration. Minimal responses were recorded to HRP-2 and Hyp2 in both 
standards: median values in the top of the curve across all plates were similar to those of the 
unexposed negative control pool (median MFI < 500 before log-transformation; see Supplementary 
Figure 1). 
 
Inter-plate variability 
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Levey-Jenning plots of IgG responses of the third point of the HP standard curve are shown in Figure 
2. Plates that fell outside of the 2 SD range of mean responses for two out of three highly immunogenic 
antigens (GLURP-R2, AMA-1 and MSP1-19) were selected to be repeated: 2 in Survey 1, 9 in Survey 2 
and 2 in Survey 3. The 5-parameter logistic regression was the optimal fit for the majority of plates 
(≥88% for all antigens; Supplementary Table 1) and was used for all standard curves. HP standard 
curves per survey are shown in Figure 3 for all antigens except HRP2 and Hyp2 (see Supplementary 
Figure 2 for the 10/198 curves). Inspection of the median and IQR of the y-inflection point was used 
to assess within and between survey variation in standard curves (Figure 4). The median and length of 
the IQR of y-inflection points was similar for Survey 1 and Survey 2 for most antigens; except for a 
smaller recorded Survey 2 median for MSP 2 CH150/9 (i.e. below the 25th percentile of Survey 1) as 
well as a larger Survey 2 IQR for MSP1-19, MSP 2 CH150/9, SBP1 and to a lesser extent MSP 2 Dd2. 
The length of the IQR for y-inflection points was generally highest in Survey 3. While for most antigens 
the median Survey 3 y-inflection point was similar to Survey 1 and 2, a smaller Survey 3 median (i.e. 
below the 25th percentile of Survey 2) was recorded for MSP 2 CH150/9, MSP 2 Dd2, GexP and 
borderline for SBP1. Standard curves for Pf, P. vivax (Pv) and P. malariae (Pm) MSP1-19 in the HP and 
10/198 standard are shown in Supplementary Figure 3. 
 
Transformation of responses between One-Step and Stepwise protocols 
IgG responses collected on the One-Step protocol were transformed using to the sigmoidal 
relationship between paired measurements on the One-Step and the Stepwise protocol (shown in 
Figure 5 for AMA-1, remaining antigenic targets in Appendix B). The goodness-of-fit (GOF) ranged from 
0.49 for Dd2 to 0.95 for AMA-1, while 15/17 antigenic targets had a GOF >0.70. Pearson’s correlation 
coefficients for transformed responses compared to Stepwise responses ranged from 0.68 for MSP 2 
Dd2 to 0.95 for AMA-1 and MSP1-19, while there was a strong correlation for 14/17 antigens (i.e. 
>0.80). Fit parameters, GOF and Pearson’s correlation coefficients are summarised per antigen in 
Supplementary Table 2. MFI results for all survey samples were transformed using these fits. 
 
Discussion 
In this study, we described the in-country application and retrospective quality control of an MBA 
simultaneously detecting IgG responses to seventeen P. falciparum recombinant antigens and 
peptides in Haiti. Antibody measurements were collected for 32,758 participant samples across three 
surveys in eighteen weeks. Results for only 0.2-0.5% of the participants per survey had to be removed 
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due to high GST responses (i.e. MFI measurements corrected for background >1000). The data 
collected for the remaining participants, represent 545,683 P. falciparum serological data points of 
which only 414 (0.08%) had to be removed due to well-specific errors such as low bead counts. The 
quality control to assess the precision of the assay was based on a specifically created positive control 
standard of hyperimmune sera from RDT positive Haitians (Haitian hyperimmune sera pool: HP). In 
addition, we included the WHO Pf 10/198 reference standard on one plate per day to compare results 
where needed [22]. The MBA was implemented as a high-throughput tool enabling rapid turnaround 
of antibody measurements for epidemiological surveys which aimed to directly inform control and 
elimination policies. 
 
Inter-plate variability was assessed using Levey-Jenning plots which showed no trends in loss or gain 
of IgG responses in the HP standard over time during assay processing other than minimal daily 
fluctuations. Daily fluctuations could have been caused by inter-technician variability, pipetting errors 
or fluctuations in laboratory temperatures and/or incubation time during assay processing. Plates that 
fell outside the mean +/- 2 SD of responses in the third point of the HP standard curve (i.e. the third 
point in the six-point dilution series of the HP standard) for two out of three highly immunogenic 
targets were repeated as previously described by others [16]. Using multiple targets for this selection 
compared to one target avoids rejecting a plate due to well-specific errors such as low bead counts or 
pipetting errors. Inter-plate variability was further assessed using 5-parameter logistic regression for 
standard curves on each plate [25,29].  Inspection of the median and IQR of the y-inflection point was 
used to assess within and between survey variation in standard curves. The median and length of the 
IQR of y-inflection points was similar for Survey 1 and Survey 2 for most antigens. The length of the 
IQR for y-inflection points was generally highest in Survey 3. For four of the included targets, the 
standard curves revealed a loss of reactivity over time (MSP2 Dd2, MSP 2 CH150/9, GexP and SBP1). 
As beads were coupled in one batch at the start of the first survey to exclude variations between bead 
batches, the loss in reactivity may be explained by these antigens being less stable after long-term 
storage. Therefore, survey results for these targets should be interpreted with caution and future use 
of these antigens would need to optimise storage and binding conditions. 
 
The application of the WHO Pf 10/198 reference standard to the MBA was recently described by 
Ubillos et al. [15]. They showed robust IgG responses to twenty-three antigens, twenty of which were 
malarial antigenic targets. Here, we reported antibody responses in this reference standard to 
fourteen novel recombinant malarial antigens of which twelve showed robust responses (Hyp-2 and 
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HRP2 did not). Responses to Pf, Pv and Pm MSP1-19 were similar to those described when the 
reference standard was developed and tested on ELISA [22]. By adding this WHO Pf 10/198 reference 
standard to one plate per day alongside the newly developed hyperimmune pool of Haitian sera on 
every plate, we were able to confirm the presence or absence of trends over time in antigen-specific 
results. However, standard curves from this pool were more variable between plates and surveys 
which could partly be due to the smaller sample size and/or this reagent may be more sensitive to 
variation in incubation times during assay processing or long-term storage. 
 
The One-Step assay protocol used in this study was recently described by Rogier et al. (Rogier et al. 
2018, in prep). Sero-prevalence estimates using this One-Step protocol were similar to those recorded 
by the conventional (Step-wise) protocol. The One-Step protocol allows rapid data collection and 
increases the ease-of-use of the assay. Nevertheless, the saturation seen at the higher range of MFI 
levels may limit the ability to detect a decrease in antibody levels after the implementation of 
interventions if the surveys are close together in time. Moreover, it would limit direct comparison of 
results with studies that collected data on a conventional protocol. Here, we used the sigmoidal 
relationship from paired log-transformed MFI measurements on each protocol to transform the 
survey data collected on the One-Step protocol to Step-wise/conventional responses. Highly 
immunogenic antigens (i.e. those eliciting high antibody titres), such as AMA-1, MSP1-19 and GLURP-
R2, generally generated a better fit than less immunogenic targets, such as H103 and Hyp2, as 
saturation was more pronounced thus creating a full sigmoidal curve. Although it should be noted that 
the comparison data was run during a specific window of time, this approach allowed for re-creation 
of Stepwise/conventional MFI measurements as shown by the strong correlation between 
transformed and Stepwise/conventional responses (i.e. Pearson’s correlation coefficient >0.8 for 
14/17 antigens).  
 
Conclusion 
In this study, we have described the successful in-country application of the MBA with highly efficient 
throughput and acceptable inter-plate variability for well-characterised antigenic targets in Haiti. This 
assay allows for rapid assessment of the exposure history of populations which can directly inform 
control and elimination policies. However, inter-plate variability was considerable for newly described 
targets with lower immunogenicity which are perhaps more sensitive to long-term storage, 
fluctuations in laboratory temperatures and/or incubation time during assay processing. Future work 
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should focus on further evaluation of the WHO Pf 10/198 in assessing stability of repeated 
measurements in serial dilutions over time as well as the effects of long-term storage conditions.  
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Table 1: Characteristics of multiplex bead assay antigen panel for three malaria transmission surveys in Haiti. iRBC: infected red blood cell. PVM: 
parasitophorous vacuole membrane. *Helb et al. [4]. 
 
Order Antigen Alias
Pathogen/Vec
tor Description Location
Expression 
tag Strain Rationale 
Antigen 
ug/mL 
beads Coupling pH Reference
1 Etramp 4 Ag 2 etr42 P. falciparum 
Early transcribed membrane antigen. 
Integral PVM protein. C-terminal iRBC, PVM GST 3D7 Recent malaria exposure* 115 7.2
Helb et al. (PMID: 26216993); 
Tetteh unpublished
2 Etramp 5 Ag 1 etr51 P. falciparum 
Early transcribed membrane antigen. 
Integral PVM protein. iRBC, PVM GST 3D7 Recent malaria exposure* 100 7.2
Spielmann et al. (PMID: 12686607); 
Tetteh unpublished
3 GexP gexp P. falciparum 
Gametocyte exported protein 18. 
Unknown function. iRBC/ Gametocyte GST 3D7 Recent malaria exposure* 200 7.2
Helb et al. (PMID: 26216993); 
Tetteh unpublished
4 H103 h103 P. falciparum H103/merozoite surface protein 11
Merozoite 
surface/rophtry neck GST 3D7 Malaria exposure 100 7.2 Pearce et al. (PMID: 15664649)
5 HRP2 hrp2 P. falciparum Histidine rich protein 2 iRBC and secreted GST Type A and B Malaria exposure 25 5 Rogier et al. (PMID: 28192523)
6 HSP40 Ag1 hsp40 P. falciparum Heat shock protein 40 iRBC GST 3D8 Recent malaria exposure* 100 7.2
Helb et al. (PMID: 26216993); 
Tetteh unpublished
7 Hyp 2 hyp2 P. falciparum Plasmodium exported protein
Hypothesised location: 
iRBC GST 3D7 Recent malaria exposure* 1000 7.2
Helb et al. (PMID: 26216993); 
Tetteh unpublished
8 LSA-1 lsa1 P. falciparum Liver surface antigen 1 Infected hepatocyte N/A
Synthesized peptide, 
Pl1043  epitope
Malaria exposure (liver 
stage) 60 5 Plucinski et al. (PMID: 29444078) 
9 MSP2 CH150/9 msp2_ch150 P. falciparum CH150/9 allele of MSP2. Full-length. Merozoite surface GST CH150/9 Malaria exposure 5 5 Roy (PMID: 16111789)
10 MSP2 Dd2 msp2_dd2 P. falciparum Dd2 allele of MSP2. Full-length. Merozoite surface GST Dd2 Malaria exposure 20 5 Taylor et al. (PMID: 7591074)
11 PfAMA1 ama1 P. falciparum Apical membrane antigen 1 Micronemes His FVO Malaria exposure 15 7.2 Collins et al. (PMID: 17192270)
12 PfGLURP R0 glurp0 P. falciparum Glutamate rich protein R0 Merozoite surface N/A
Synthesized peptide, R0 
fragment Malaria exposure 30 5 Kerkhof et al. (PMID: 27809852)
13 PfGLURP R2 glurp2 P. falciparum Glutamate rich protein R2 Merozoite surface Hisx6 F32 Malaria exposure 15 7.2 Theisen et al. (PMID: 7719909)
14 PfMSP1-19 msp119 P. falciparum 19kDa fragment of MSP1 molecule Merozoite surface GST Wellcome Malaria exposure 20 7.2
Burghaus and Holder (PMID: 
8078519) 
15 PfSEA sea P. falciparum Schizont egress antigen iRBC GST 3D7 Malaria exposure 20 5
Raj et al. (PMID: 24855263); Tetteh 
unpublished
16 PmMSP1-19 pmmsp119 P. vivax 19kDa fragment of MSP1 molecule Merozoite surface GST Pm China I Pv Malaria exposure 20 5 Priest et al. (PMID: 30413163)
17 PvMSP1-19 pvmsp119 P. malariae 19kDa fragment of MSP1 molecule Merozoite surface GST Pv Belem Pm Malaria exposure 20 5 Priest et al. (PMID: 30413163)
18 rCSP rcsp P. falciparum Circumsporozoite surface protein Sporozoite N/A 3D7
Recent malaria exposure* 
(sporozoite stage) 60 7.2
Kastenmuller et al. (PMID: 
23275094) 
19 SBP1 sbp1 P. falciparum Skeleton-binding protein; Maurer's cleft. iRBC GST 3D7 Malaria exposure 15 5
Gruring et al. (PMID: 21266965); 
Tetteh unpublished
21 GST gst S. japonicum Glutathione S-transferase
Correct for background 
reactivity due to GST-tag 20 5 J. Priest/CDC
22 Tetanus Toxoid tt C. tetani Tetanus Toxoid
Vaccination target: internal 
“positive” control 12.5 5
Massachusetts Biologic 
Laboratories
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Table 2: Number of samples and observations for which Immunoglobulin G (IgG) antibody responses 
were successfully collected using a multiplex bead assay across three malaria transmission surveys 
in Haiti. 
 Survey 1 
 
Survey 2 Survey 3 
Plates, n 71 257 59 
Samples, n 
Proportion of previous n 
   
- Collected in the field 
 
6006 21891 5034 
- Received/processed at the 
lab 
5956 
99.17% 
21801 
99.59% 
5001 
99.34% 
- GST reading available 5922 
99.43% 
21336 
97.87% 
4989 
99.76% 
- Acceptable GST reactivity 5898 
99.59% 
21234 
99.52% 
4967 
99.56% 
Observations*, n 
Loss, n 
   
- All antigens (n=21) 
Loss 
123,850 
8 
445,787 
127 
103,987 
320 
- Plasmodium antigens (n=19) 
Loss 
112,054 
8 
403,325 
121 
94,059 
314 
- P. falciparum antigens (n=17) 
Loss 
100,260 
6 
360,872 
106 
84,137 
302 
*Unique IgG observations successfully collected (i.e. number of participants multiplied by number of 
antigens/peptides to which antibody responses were collected). 
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Figure 1: Antibody reactivity profile of standards of hyperimmune sera. MFI: Median fluorescence 
intensity values were corrected for background reactivity of blank responses and log-transformed (y-
axis). For antigen (x-axis) acronyms see Table 1. In addition to malarial antigens, tetanus toxoid (tt) 
and glutathione S-transferase (gst) responses are shown. HP: Haitian hyperimmune sera pool (for 
details see main text). NIBSC: Plasmodium falciparum 10/198 WHO standard [22]. The HP curve was 
run on every plate, while the 10/198 curve was run on one plate per day. Responses to the first point 
of the curve are shown, with a serum concentration of 1:200 for the HP and 1:100 for the 10/198 
standard. Antigens are ordered by median HP responses. 
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Figure 2: Levey-Jenning charts of antibody responses in the standard of Haitian hyperimmune sera 
across all plates. MFI: Median fluorescence intensity; values were corrected for background reactivity 
of blank responses and log-transformed. HP: Haitian hyperimmune sera pool (for details see main 
text).  Responses in the third point of the curve (serum concentration of 1:5,000) are shown across 
three surveys. The mean plus/minus two times the standard deviation across responses per survey 
are shown in dashed red lines. 
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Figure 3: Average standard curves of the standard of Haitian hyperimmune sera for each survey. 
MFI: Median fluorescence intensity. For each plate and antigen, HP standard curves were fitted using 
5-parameter logistic regression. Standard curves were only fitted if the non-log-transformed MFI of at 
least one of the dilution points was larger than 100. Using the curve parameters, MFI values were 
predicted across a sequence of 200 values of standard curve concentrations for each of the plates. 
Standard curves per survey were plotted using the generalized additive model method and the 
interquartile range is shown in vertical lines at each of the dilution steps of the standard curve.  
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Figure 4: Median and interquartile range of predicted y-inflection points of standard curves per 
survey using the Haitian standard of hyperimmune sera. Median and interquartile range of the 
predicted y-inflection points from standard curves for all plates using 5-parameter logistic regression. 
For antigen (x-axis) acronyms see Table 1. Antigens are ordered by median responses as shown in 
Figure 1.  
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Figure 5: Transformation of antibody responses between the OneStep and Stepwise multiplex bead 
assay protocols for AMA-1. MFI: Median fluorescence intensity. The sigmoidal relationship of paired 
measurements was obtained using 804 samples processed on the One-Step and the 
Stepwise/conventional assay protocol (Rogier et al., in prep). Recorded responses lower than blank 
responses were replaced with the average of blank MFI values of the One-Step protocol across all 
plates by antigen. Measurements from the One-Step protocol were transformed using the sigmoidal 
fit. Samples that fell below the bottom asymptote or over the upper asymptote, were replaced by the 
lowest and highest values that the model could estimate. Plots for remaining antigenic targets are in 
Appendix B and curve parameters are in Supplementary Table 2. (a) Scatter plot of paired 
measurements with 5-parameter logistic regression in red line. (b) Scatter of transformed responses 
compared to measurements using the Stepwise/conventional protocol. (c) Histograms of One-Step, 
Stepwise/conventional and transformed antibody measurements. (d) Box plots of One-Step, 
Stepwise/conventional and transformed antibody measurements over age groups.  
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Supplementary Tables 
Supplementary Table 1: Frequency of plates with n-parameter logistic regression fit for standard 
curves per antigen across three surveys in Haiti. For antigen abbreviations, see Chapter 5, Table 1. 
HP: standard of Haitian hyperimmune sera (for details see main text). 10/198: Plasmodium falciparum 
10/198 WHO hyperimmune standard [22]. The total number of plates is variable per antigen as logistic 
regression fits for standard curves were only applied if the non-log-transformed MFI of at least one of 
the dilution points was larger than 100. 
Antigen Standard n-parameter 
3 4 5 
msp2_ch150 HP 1 0 354 
10/198 0 7 42 
msp2_dd2 HP 1 4 351 
10/198 0 15 35 
etr42 HP 0 14 342 
10/198 0 6 44 
etr51 HP 0 0 357 
10/198 0 2 48 
Gexp HP 0 6 350 
10/198 0 16 34 
glurp0 HP 0 1 356 
10/198 0 12 38 
glurp2 HP 0 10 347 
10/198 5 17 28 
h103 HP 1 14 198 
10/198 0 4 46 
hsp40 HP 0 10 347 
10/198 0 2 48 
ama1 HP 0 42 315 
10/198 0 20 30 
msp119 HP 6 24 326 
10/198 2 23 25 
lsa1 HP 0 0 357 
10/198 2 16 32 
rcsp HP 0 4 353 
10/198 0 6 44 
sbp1 HP 0 3 354 
10/198 0 6 45 
sea HP 1 13 325 
10/198 0 3 47 
tt HP 0 3 354 
10/198 2 30 18 
pmmsp HP 0 79 276 
10/198 2 12 36 
pvmsp HP 0 8 58 
10/198 0 5 23 
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Supplementary Table 2: Curve parameters of logistic regression fits for antibody responses recorded 
by the OneStep and Stepwise multiplex bead assay protocol for each antigen. Median fluorescence 
intensity (MFI) measurements were corrected for background reactivity of blank responses and 
natural log-transformed. The sigmoidal relationship of paired median fluorescence intensity (MFI) 
measurements was obtained using 804 samples processed on the One-Step and the Stepwise assay 
protocol (Rogier et al., in preparation, Appendix A). Curve parameters from sigmoidal logistic 
regression fits include the number of parameters (npar), the top asymptote (max), the mid-point 
(mid), the slope, the bottom asymptote (min), the asymmetry parameter (s) and the goodness-of-fit 
estimates (GOF). Recorded MFI measurements lower than blank responses were replaced with the 
average of blank MFI values of the One-Step protocol across all plates by antigen. Measurements from 
the One-Step protocol were transformed using the sigmoidal fit. Samples that fell below the bottom 
asymptote or over the upper asymptote, were replaced by the lowest and highest values that the 
model could estimate. The Pearson correlation coefficients for transformed responses compared to 
Stepwise responses is also included this table (Pearson).  
Antigen npar max mid slope min s gof Pearson 
msp2_ch150 5 11.136 6.470 0.485 3.462 0.903 0.829 0.868 
ama1 5 10.988 4.542 0.485 3.362 1.978 0.946 0.954 
sbp1 5 11.768 5.076 0.216 1.812 1.206 0.739 0.867 
msp119 5 11.283 1.187 0.294 3.689 18.427 0.920 0.949 
hyp2 5 7.567 3.295 0.401 3.832 4.138 0.736 0.855 
gexp 4 24.366 6.528 0.056 -9.926 1.000 0.794 0.891 
lsa1 4 10.951 5.835 0.455 3.380 1.000 0.764 0.783 
hrp2 5 10.851 5.110 0.489 3.858 1.990 0.803 0.823 
glurp0 5 10.847 8.836 1.313 3.221 0.145 0.843 0.802 
etr51 5 10.697 7.489 0.561 2.970 0.399 0.774 0.804 
hsp40 5 10.262 6.332 3.942 3.427 0.095 0.846 0.835 
rcsp 5 11.126 7.274 0.571 2.957 0.402 0.839 0.874 
h103 4 11.203 6.679 0.380 3.526 1.000 0.671 0.716 
glurp2 5 11.154 8.213 0.645 3.309 0.489 0.913 0.900 
etr42 5 10.074 7.199 2.242 3.182 0.105 0.791 0.840 
Sea 5 11.340 6.290 0.379 3.967 1.504 0.837 0.839 
msp2_dd2 4 9.998 5.982 0.395 3.195 1.000 0.488 0.684 
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Supplementary Figures 
 
 
Supplementary Figure 1: Antibody reactivity profile of positive control standards of hyperimmune 
sera as well as a and negative control standard of malaria-unexposed sera. Median fluorescence 
intensity (MFI) measurements were corrected for background reactivity of blank responses and 
natural log-transformed (y-axis). For antigen (x-axis) abbreviations see Chapter 5, Table 1. In addition 
to malarial antigens, tetanus toxoid (tt) and glutathione S-transferase (gst) responses are shown. HP: 
standard of Haitian hyperimmune sera (for details see main text). NIBSC: Plasmodium falciparum 
10/198 WHO hyperimmune standard [22]. Neg: pool of 10 serum samples from malaria unexposed 
individuals from the UK. The HP curve was run on every plate, while the 10/198 curve was run on one 
plate per day. Responses to the first point of the curve are shown, with a serum concentration of 1:200 
for the HP and Neg, and 1:100 for the 10/198 standard. Antigens are ordered by median HP responses. 
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Supplementary Figure 2: Average standard curves of the 10/198 WHO positive control standard of 
hyperimmune sera for each survey. Median fluorescence intensity (MFI) measurements were 
corrected for background reactivity of blank responses and natural log-transformed. MFI values were 
converted to proportions using the minimum and maximum MFI values for all standard curves across 
all antigens (2.07 and 11.17 respectively). For antigen abbreviations see Chapter 5, Table 1. For each 
plate and antigen, 10/198 WHO standard curves were fitted using 5-parameter logistic regression. 
Standard curves were only fitted if the non-log-transformed MFI of at least one of the dilution points 
was larger than 100. Using the curve parameters, MFI values were predicted across a sequence of 200 
values of standard curve concentrations for each of the plates. Standard curves per survey were 
plotted using the generalized additive model method and the interquartile range is shown in vertical 
lines at each of the dilution steps of the standard curve.  
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Supplementary Figure 3: Average standard curves of the Haitian (HP, top) and 10/198 WHO (NIBSC, 
bottom) positive control standard of hyperimmune sera for each survey for the Plasmodium 
falciparum, P. vivax and P. malariae 19 kDa merozoite surface protein 1. Median fluorescence 
intensity (MFI) measurements were corrected for background reactivity of blank responses and 
natural log-transformed. MFI values were converted to proportions using the minimum and maximum 
MFI values for all standard curves across all antigens (2.07 and 11.17 respectively). For antigen 
abbreviations see Chapter 5, Table 1. For each plate and antigen, HP and 10/198 WHO standard curves 
were fitted using 5-parameter logistic regression. Standard curves were only fitted if the non-log-
transformed MFI of at least one of the dilution points was larger than 100. Using the curve parameters, 
MFI values were predicted across a sequence of 200 values of standard curve concentrations for each 
of the plates. Standard curves per survey were plotted using the generalized additive model method 
and the interquartile range is shown in vertical lines at each of the dilution steps of the standard curve.  
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Additional File: Comparison of median fluorescence intensity 
measures in serum compared to dried blood spot eluate using 
OneStep and Stepwise multiplex bead assay protocols 
Corran et al. have previously shown that paired samples of serum and blood spots from Tanzania 
showed similar recoveries of antibodies using enzyme-linked immunosorbent assay (ELISA) [1]. 
However, how these compare for multiplex bead assay (MBA) remains largely unknown. To compare 
MBA median fluorescence intensity (MFI) measures in serum and DBS eluate, samples from survey 
participants in Haiti were analysed.  
Methods 
Participant samples were collected as part of Survey 1 in Artibonite, central Haiti (Chapter 5). Whole-
blood from finger-prick were collected in EDTA microtainers (Safe-T-Fill™ Capillary Blood Collection 
Systems: EDTA, # 07 7053, RAM Scientific Inc., Yonkers, NY). Three 60 µl spots were pipetted on 
Whatmann 903 cards (GE Healthcare) at the end of each day in a field laboratory in Artibonite. 
Whatmann 903 cards were dried overnight and stored at ambient temperate until transport. 
Remaining whole blood was kept in EDTA microtainers at +4°C in the field laboratory. DBS and EDTA 
microtainers were transported to the Laboratoire National de Santé Publique (LNSP) in Port-au-Prince 
once per week. At LNSP, DBS and EDTA microtainers were stored at +4°C. Serum was separated using 
centrifugation at 5000g for 2 minutes and aliquoted to 96-well storage plates (Axygen 500 µl round-
bottom, Fisher Scientific, # 14-222-234) within 3 days after arrival. Separate 96-well storage plates 
were prepared diluting serum and DBS eluate 1:100 in buffer B. These were incubated overnight and 
stored at +4°C until sample processing. 
Antimalarial IgG responses in diluted serum and DBS eluate were analysed by MBA using the OneStep 
and Stepwise (i.e. Standard/conventional) protocol. Details on these protocols can be found in 
Chapter 5 and Appendix A. Serum and DBS eluate was tested at a final concentration of 1:200. MFI 
values were recorded on the MAGPIX with Bio-Plex Manager™ MP software and corrected for blank 
(buffer B) responses as described in Chapter 5. We aimed to test the first 800 samples that came into 
the lab for Survey 1 which resulted in 796 DBS samples (loss due to well-specific errors such as low 
bead counts), for which 712 paired serum samples were available (loss due to insufficient serum 
available to aliquot in the field laboratory or at LNSP). Statistical analyses were performed in R Studio 
Version 1.1.456.  
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Results 
Antibodies to six antigens were selected: three relatively high immunogenicity targets (GLURP-R2, 
AMA-1 and Rh2-2030) and three relatively low immunogenicity targets (Etramp 5 Ag 1, HSP40 and 
LSA-1). Visual inspection of scatter plots comparing MFI measurements in serum and DBS eluate using 
the Stepwise MBA protocol reveals a strong linear correlation, though generally MFIs recorded in 
serum are above the line of equality (Figure 1). Some clear outliers can be seen, mostly for GLURP-R2 
(n~11). For the OneStep protocol, the same pattern of increased MFI measurements in serum is 
observed though overall comparisons are less linear and correlated (Figure 2). MFIs in serum saturate 
for GLURP-R2.  
Conclusion 
Paired DBS and serum samples show similar recoveries of antibodies using the MBA Stepwise protocol. 
The minimal increase in MFI measurements for serum samples is as expected as perhaps not all 
antibodies elute efficiently from DBS. For the OneStep protocol, recoveries were less linear possibly 
due to differences in incubation times (as incubation is overnight and therefore time windows may 
vary) or prozone phenomenon (i.e. false-negative results resulting from high antibody titres) [2]. 
Outliers on either protocol may also be due to pipetting errors. 
DBS are logistically more convenient than serum samples due to ease of collection, storage and 
transportation. Moreover, DBS are simultaneously a source of DNA for PCR-based methods to 
diagnose malaria infections. The fact that similar antibody recoveries were shown by MBA between 
these sample types, confirms previously described results for ELISA [1]. Based on these results, all 
participant samples in remaining project surveys were collected on Whatman 903 cards and stored as 
DBS. 
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Figure 1: Comparison of median fluorescence intensity (MFI) measures in serum (y-axes) and dried blood spots (DBS) eluate (x-axes) as recorded by the 
multiplex bead assay Stepwise protocol. MFI values are natural log-transformed and corrected for background reactivity (i.e. blank, buffer B responses). 
Black dots represent 712 participant samples from Survey 1, while the line of equality is shown in black. For antigen abbreviations, see Table 1 (Chapter 5). 
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Figure 2: Comparison of median fluorescence intensity (MFI) measures in serum (y-axes) and dried blood spots (DBS) eluate (x-axes) as recorded by the 
multiplex bead assay OneStep protocol. MFI values are natural log-transformed and corrected for background reactivity (i.e. blank, buffer B responses). Black 
dots represent 712 participant samples from Survey 1, while the line of equality is shown in black. For antigen abbreviations, see Table 1 (Chapter 5)
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Abstract 
Background 
Antimalarial antibody measurements are unique as they reflect historical and recent exposure to 
malaria. They may provide additional information in monitoring transmission alongside prevalence of 
infection in low endemic or pre-elimination settings. Currently, there is no standardised test to detect 
antimalarial antibodies for epidemiological use. However, standardised commercial enzyme-linked 
immunosorbent assays (ELISA) are available to screen donor blood products. Here we compare five 
commercially available ELISA kits (coded A, B, C, D and E) for their relative performance in search of a 
standardised tool for epidemiological use, with a focus on supporting claims of absence of malaria 
transmission.  
Results 
Assay performance was firstly evaluated using serum samples from malaria unexposed individuals as 
well as Toxoplasma-infected individuals. Three out of five kits showed high specificity (98-99%), low 
cross-reactivity (0-3%) and were considered user-friendly (kit A, B and E). Two kits (A and E), that were 
still commercially available, were taken forward for epidemiological evaluation. Samples from a low, 
unstable transmission setting (Praia, Cape Verde; n=1432) and a pre-elimination setting (Bataan, the 
Philippines; n=2050) were tested. Serological results from kit A overlap with previously described 
transmission patterns and passively detected case counts in both settings. Results from kit E did not 
show the expected increase in seroprevalence by age nor an overlap with previously described 
transmission patterns.  
Conclusion 
One out of the five commercial ELISA kit was considered applicable for epidemiological use and 
accurately described transmission patterns in two endemic settings. The use of simple and 
standardised serological tools to document the absence of malaria transmission can inform control 
and elimination programs by confirming that regions are free from malaria.  
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Introduction 
A unique property of using antimalarial antibody responses as a measure of transmission is that when 
combined with age, they reflect a population’s exposure history [1–3]. Antibody measures can 
therefore re-create transmission patterns over time and any fall in, or absence of, antibodies can be 
interpreted as a decrease in exposure to malaria infections or cessation of transmission. Intuitively, 
this cumulative metric of exposure to malaria would result in the need for smaller sample sizes to 
describe transmission at low levels compared to metrics that seek for the proportion of infected 
individuals in a cross-sectional survey (parasite rate) [4]. 
Historically, the absence of antibodies in children has been used as proof of cessation of transmission 
in Greece and Mauritius [5,6]. In these studies, antibody responses to crude parasite extract were 
determined using an immunofluorescence antibody test (IFAT). More recently, results from Aneityum 
and Iran suggested absence of transmission by assessing antibody responses to individual 
recombinant antigens (AMA-1 and MSP-119) [7,8] or schizont extract [7] using an enzyme-linked 
immunosorbent assay (ELISA). Similar to the historical studies, children showed no antimalarial 
antibody responses, while some adults did have antimalarial antibodies owing to the persistence of 
antibodies (and/or memory B cells) once acquired [9–11]. The ELISA platform is considered more 
objective than IFAT as antibody reactivity is determined by measuring optical density (OD) with a 
spectrophotometer rather than visual inspection of the strength of fluorescence using a fluorescence 
microscope [12]. However, at present, there is no standardised ELISA protocol to measure malaria 
antibodies for epidemiological use: standard operating procedures, positive controls (i.e. 
hyperimmune sera) and negative controls (i.e. unexposed sera), as well as methods of normalisation 
vary between research groups and studies, which makes direct comparison of results between 
countries or populations challenging [4,13].  
There are several commercially available ELISA kits, for which production and operating procedures 
are standardised. These have been used to screen blood donations for evidence of malaria exposure 
prior to transfusion [14–19]. Some have applied these in an epidemiological context, such as in 
Ethiopia [20]. To our knowledge, a comparison of the performance of multiple commercially available 
ELISA kits for epidemiological characterisation of malaria transmission has not been done to date. 
Therefore, we aimed to compare five commercially available ELISA kits for their applicability and 
performance in describing malaria transmission. We firstly assessed applicability by comparing assay 
characteristics such as ease-of-use, specificity, cross-reactivity and the amount of serum needed to 
test a sample. Secondly, we tested samples from an area of low, unstable malaria transmission (Praia, 
Cape Verde) and a pre-elimination area (Bataan, the Philippines). 
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Methods 
Study population 
Phase I: Assay performance 
Assay performance was based on the proportion of samples correctly identified as negative using 223 
samples from malaria unexposed UK donors (to assess specificity) as well as 191 samples from 
Toxoplasma-infected, malaria unexposed UK donors (to assess cross-reactivity). Malaria naivety was 
defined using a questionnaire to exclude malaria risk at the time of donation [14]. Toxoplasma was 
diagnosed with nine commercially available Toxoplasma IgG and IgM tests (Supplementary 
Information I) and was considered positive if it tested positive for any of these tests (J. Newham/A. 
Kitchen; unpublished data). Furthermore, costs, the amount of serum needed to test a sample, and 
ease-of-use were assessed. For ease-of-us, a composite measure was created based on the number 
of incubation steps, total incubation time, need for sample preparation and whether reagents were 
ready-to-use. 
Phase II: Epidemiological characterisation 
Samples were collected in February 2017 in Bataan, the Philippines (Figure 1a), which saw a steep 
decline in incidence in the 1990s [21,22] and was declared malaria-free in 2017 (Provincial 
Epidemiology and Surveillance Unit – Bataan, Malaria Surveillance Report; 2005-2017). Secondly, 
samples were collected in historical malaria hotspots in Cidade daPraia, Cape Verde (Foton/Tira-
Chapéu, Várzea/Taiti and Achada de Santo António; Figure 1b-c) which has seen unstable, low 
transmission since late 1980s with occasional outbreaks [23–25]. The most recent outbreak started 
mid-July 2017, with peak cases around the end of August and the end of October [26,27]. The majority 
of samples in the current study were collected before this outbreak (June-July 2017).  
A two-stage cluster randomised sampling design was used with village or a sub-regional administrative 
unit as primary sampling unit and household as secondary sampling unit. A sample size of 2000 
individuals was initially defined for each setting. Under a cross-sectional survey, an entomological 
inoculation rate of 0.01 and the use of the MSP119 antigen, this sample size was expected to generate 
a 95% confidence interval for seroprevalence between 4.7% and 6.8% and for the SCR of 0.0029-
0.0043 for African settings, and 6.1% and 8.5% and 0.0029-0.0043 for non-African settings [28]. This 
sample size predicted a power greater than 90% in detecting malaria elimination events occurring at 
least three years before data collection [29].  For the Cape Verdean setting, staff constraints and study 
feasibility led to a reduction in the initial sample size to approximately 1,500 individuals. This new 
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sample size would generate a 95% confidence interval for seroprevalence between 4.5% and 7.0% and 
for the SCR of 0.0028-0.0044.   
All household members over 6 months old who provided consent or assent were included across 
randomly selected households. A short questionnaire was conducted including demographic 
information and reported history of malaria. Up to 500µl of whole blood from finger-prick were 
collected using BD microtainers with EDTA (Becton-Dickinson, Franklin Lakes, New Jersey). Serum was 
separated at collaborating institutions in-country and were stored at -20°C until shipment on dry ice 
to the London School of Hygiene and Tropical Medicine. Serum was stored at -20°C until sample 
processing. 
Commercial ELISA kits for antimalarial antibody detection 
Five commercial ELISA kits were used according to their instruction manuals (included in Appendix C). 
Kits were coded alphabetically to reduce subjectivity in the interpretation of results (Supplementary 
Information II). An overview of the standard operating procedure for each of the included kits is shown 
in Supplementary Table 1. Optical density (OD) measures were read with a spectrophotometer 
(Dynex® Technologies) at a wavelength of 450nm with a reference filter of 630 nm according to the 
instruction manuals. OD measures were corrected for blank responses according to kit manuals 
(hereafter: ODcorr). 
Statistical analyses 
All statistical analyses were performed in RStudio© Version 1.1.456. For Phase I, thresholds for 
seropositivity were calculated according to instruction manuals. For the epidemiological 
characterisation in endemic settings (Phase II), only participants with sufficient serum available for all 
tests (~65 µl) and with age data available were included. Antibody responses from infants under the 
age of 1 year old were removed due to the possible confounding effects of maternally derived 
antibodies. In addition to the seropositivity as assigned by the kit instructions, the optimal number of 
latent serological populations in the antibody data was estimated using mixtures of skewed normal 
distributions. These distributions include mixtures of normal distributions often used in malaria sero-
epidemiological analyses. The optimal number of components was determined by estimating models 
with one to five components and using Akaike’s and Bayesian information criteria for the respective 
model comparison.  If more than one distribution was detected in the data, seropositivity was defined 
at three standard deviations plus the mean of the distribution with the lowest mean (i.e. the 
distributions with the lowest mean are assumed seronegatives in the population tested). This analysis 
was performed using the mixsmsn and sn packages [30,31]. A simple reversible catalytic model was 
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fitted to the seroprevalence and age data for each endemic setting using maximum likelihood methods 
[2,3]. The model generates a seroconversion rate (SCR) which reflects the rate at which a population 
becomes seropositive and is an indication of the force of infection, and seroreversion rate (SRR) which 
reflects the rate at which the population reverts to seronegative. This model was used to generate 
seroconversion curves (i.e. age seroprevalence curves). If visual examination of the seroconversion 
curve suggested that a change in transmission had occurred, a model with two SCRs was fitted to 
determine when the change most likely had occurred as described previously [1,7]. A likelihood ratio 
test was used to determine if the model allowing for two SCRs fitted the data better than the model 
allowing for one SCR (p<0.05). Furthermore, age-antibody curves using continuous antibody response 
data were assessed using the tmleAb R package described by Arnold et al. [32]. In short, mean antibody 
responses (ODcorr) were modelled as a function of age using a super learner algorithm in which an 
ensemble of models and algorithms are used. The ensemble included: the simple mean, generalized 
linear models, generalized additive models with natural splines, locally weighted regression (lowess) 
and the recently described antibody acquisition model with constant rates [33]. Coefficients 
representing the weights for each algorithm were recorded. Logistic regression analysis was done to 
identify demographic and household factors associated with seropositivity in each setting. An adjusted 
model was created with factors testing statistically significant in univariate analysis (p-value <0.05). 
Ethical approval 
Ethical approval to test anonymised UK donor samples collected by Public Health England/NHS Blood 
and Transplant was obtained through the LSHTM Research Ethics Committee (11684). For the surveys 
in Cape Verde and the Philippines, ethical approval was obtained through the LSHTM Research Ethics 
Committee (11684), the Comissão de ética nacional em Pesquisa da Saúde in Cape Verde (65/2016) 
and the Research Institute for Tropical Medicine in the Philippines (2016-26). All survey participants 
provided written informed consent or assent. 
 
Results 
Phase I: Assay performance 
Manuals from commercial kits report sensitivities ≥93% and specificities ≥96% (Table 1). The 
proportion of samples correctly identified as negative either for malaria unexposed individuals or 
those with other infections (Toxoplasma-positive) was high across all kits (>96%) except for kit D (81% 
and 84%, respectively). Costs per sample were highest for kit C, D and E (≥£1.71 compared to ≤£1.32 
for kit A and B), while kit C needed the highest volume of serum (150 µl compared to ≤50 µl for the 
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other kits) and was considered least user-friendly (Table 2 and Supplementary Table 1). Based on these 
results, three commercial kits were taken forward to compare their use for epidemiological 
characterisation (kit C and D were dropped). However, commercial production of kit B was 
discontinued after finalisation of Phase I and it was therefore unavailable; thus, only kit A and E were 
taken forward. 
Phase II: Epidemiological characterisation 
After aliquoting serum from Eppendorf tubes into deep well plates, samples were processed over two 
days for Cape Verde (sixteen 96-well plates) and 3 days for the Philippines (twenty-two 96-well plates). 
In Cape Verde, 1396 out of 1432 samples collected were available for analyses (no age data available 
or younger than 1 year old, n=33; not enough serum available for all tests, n=11). In the Philippines, 
1824 out of 2050 collected were available (no age data available or younger than 1 year old, n=11; not 
enough serum available for all tests, n=179; participant lived outside main study area, n=36).  
Antibody metrics for transmission intensity 
Kit E did not show the expected increase in age-specific seroprevalence and seroconversion curves did 
not reflect known (historical) transmission patterns (Supplementary Information III). For kit A, 
depending on the threshold used for seropositivity (detection of latent distributions within the 
antibody data recorded or according to kit manual; see Supplementary Figure 1), seroprevalence 
ranged from 15.4 (95% CI: 13.7% – 17.1%) to 18.6% (16.9% – 20.5%) in Bataan, the Philippines and 
4.8% (3.7% – 6.1%) to 6.5% (5.3% – 7.9%) in Praia, Cape Verde. Hereafter, only results using 
seropositivity according to the distribution approach will be presented in text but results for both are 
presented in figure legends. 
In Bataan, the Philippines, change points in the seroconversion curves were estimated at 21 (21 – 21; 
Figure 2c), which coincides with a sudden drop in reported cases at local health facilities (Figure 2a). 
The estimate of the recent SCR was 0.0002 (0.0001 – 0.0016) and an overall SRR of 0.0113 (0.0005 – 
0.0188) year-1. Age-antibody curves using continuous antibody response data (i.e. ODcorr), showed a 
similar pattern to the seroconversion curve (Figure 2c). Seroprevalence in those born after this 
decrease in transmission was minimal, 0.6% (5/878), they did not report history of malaria and the 
median age was 15 (9 – 20). In individuals aged 37 years and older (n=534), seroprevalence was higher 
in men (48.4% compared to 31.9% in women, Chi squared test p<0.001; Figure 2d). 
In Cape Verde, both historical and recent transmission were low as represented by the seroconversion 
curve (Figure 3b) which is reflected in the low case counts since the late 1980s (Figure 3a). The SCR 
was estimated at 0.0018 (0.0013 – 0.0026) and SRR at 0.0000 (0.000 – 0.0156) year-1, while no 
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statistically significant change point was observed. However, age-antibody curves showed a peak in 
antibody responses around 30-year olds as well as 45 to 50-year olds (Figure 3c). Seroprevalence by 
gender reveals that seropositivity is higher in men aged 30 to 46 (10.1%, 8/79) compared to women 
(0.5%, 8/176) although this difference was not statistically significant (Fisher’s Exact test p=0.100).  
Associations with seropositivity  
In the Philippines, adjusted logistic regression analysis of factors associated with seropositivity for kit 
A identified: adults, males, bed net use and self-reported history of malaria (Table 3). In Cape Verde, 
factors associated with seropositivity were younger children (1 to 5 year olds), no use of preventions 
for bites, bed net use and self-reported history of malaria. 
 
Discussion 
There is historical evidence that antibody detection may help in certifying areas malaria-free [5,6], but 
there is no standardised approach available. The application of a standardised assay to detect 
antimalarial antibodies is an essential step in the evaluation of the use of serological data to support 
claims of absence of transmission. Commercially available ELISA kits undergo rigid standardisation 
processes and have been applied to screen blood products prior to donation to minimise risks of 
transfusion-transmitted malaria [14–19]. Here, we compared five commercial ELISA kits for their 
applicability (Phase I) and performance (Phase II) in epidemiological characterisation of malaria 
transmission at low endemicity and pre-elimination. 
Kit C and D were not considered applicable for use in epidemiological surveys owing to relatively high 
costs per sample (kit C, D and E ≥£1.71 compared to ≤£1.32 for kit A and B) and low ease-of-use due 
to longer incubation times (150 min and 135 min; compared to 105 min for kit E and 90 min for kit A 
and B), the need for sample preparation, the need for reagent preparation and an additional 
incubation step for kit C. Although kit E also required samples to be prepared, all reagents were ready-
to-use; and while kit A needed one reagent to be prepared, samples did not need preparation, and 
incubation steps and time were least compared to other kits. In addition, kit C showed relatively low 
specificity (82% compared to ≥98% for the other kits) and high cross-reactivity (16% compared to ≤2% 
for the other kits), while it required the most serum to run a sample (150 µl compared to ≤50 µl for 
the other kits). High specificity and low cross-reactivity are essential in the use of any assay, especially 
in the context of determining the absence of transmission (i.e. minimizing the risk of false-positives) 
[34]. Likewise, sensitivity is an important factor, which we did not test for in this study. However, 
instruction manuals report sensitivities ≥93%, while manuals for kit A and B also included the number 
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of samples tested for their assessment of sensitivity (13,608 and 450 patient samples). Sensitivity as 
assessed in other research studies is discussed below. Finally, the amount of serum needed per sample 
is an important factor as most malaria transmission surveys use finger-prick blood [35] and ideally, 
sufficient sample would be collected from each participant to be able to repeat the assay if needed. 
Therefore, 150 µl of serum was not considered feasible (kit C). Based on these findings, kit A and B 
were considered most appropriate for use in large-scale epidemiological surveys, followed by kit E 
(owing to higher costs per sample and relatively long incubation times compared to kit A and B but an 
otherwise similar performance). Unfortunately, commercial production of kit B was discontinued after 
finalisation of Phase I. 
To assess the performance of kit A and E in epidemiological characterisation, samples from Bataan, 
the Philippines (declared malaria-free in 2017) and Praia, Cape Verde (unstable, low transmission) 
were tested. Results from kit A described historical and recent malaria transmission in Bataan 
accurately, both for metrics using seropositivity and for antibody density over age. Seroconversion 
curves showed a change in the force of infection which coincides with a sudden decrease in passively 
detected malaria cases in 1995 [21] following the roll-out of community-based volunteers to improve 
access to malaria diagnosis in 1994 [22]. Seroprevalence in those born since this sudden decrease in 
transmission was low (i.e. 0.6%). Whether these represent false-positive results or true responses 
following asymptomatic, low-density infections or infections acquired outside the study area, is 
unknown. The recent SCR approximated zero with ~0.02% of the population seroconverting, which is 
lower than those recorded in Sri Lanka during pre-elimination using a research-based ELISA protocol 
[36]. For Cape Verde, the low levels of transmission over the past decades were correctly identified as 
shown by the low, constant SCR recorded by kit A (i.e. ~0.18% of the population seroconverts per 
year). The age-antibody curve revealed a peak in antibody titre around 30- and 45-50-year olds and 
increased seroprevalence was seen in men, possibly due to work-related risk of malaria infection (i.e. 
work involving night-shifts) or travel-related risk (though this was not statistically significant). This 
pattern has previously been described for passively collected malaria case counts recorded between 
2007-2009, as two thirds of the reported cases were in adult men [23]; and for those recorded 
between 2010-2016 as 77% of the cases were in males and 82% of the cases in individuals older than 
20 years of age [30]. Importantly, an outbreak of malaria occurred in Cape Verde in the final weeks of 
sample collection for the current study [26]. Both kits (A and E) detect IgM as well as IgG, which is an 
added advantage over most research-based protocols. As IgM is an early responder following malaria 
re-infection [37,38], separately assessing IgG and IgM may help in distinguishing recent compared to 
historical transmission more accurately. Results recorded by kit E did not show the expected increase 
in age-specific seroprevalence and seroconversion curves did not reflect malaria transmission patterns 
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based on passively collected malaria case counts. It was therefore not considered appropriate for 
epidemiological characterisation of transmission.  
Many studies have described the overlap in serological results with other malaria metrics using a 
research-based ELISA, detecting antibodies to asexual parasite antigens in endemic settings [1–4,39]. 
To our knowledge, only two other studies have used a commercially available ELISA kit for 
epidemiological characterisation of malaria in an endemic settings [20,40]. Birhanu et al. assessed the 
parasite rate by microscopy and RDT alongside antimalarial antibody detection by kit A in Ethiopian 
children aged 2-9 years old. They showed a parasite rate of zero percent in the majority of study sites 
while seroprevalence differed considerably (1.6 – 55.7%) [20]. In Iran, Kit D was used to test samples 
from a hypoendemic region and it recorded seroprevalence at <1% in those aged 20 years or younger. 
All participants were microscopy negative and had no circulating HRP2 antigen [40]. In contrast, many 
have assessed the test performance (i.e. sensitivity/specificity) of commercial ELISA kits using samples 
from malaria patients or those without malaria risk (i.e. no travel to endemic settings). Alongside kits 
not assessed in this study, kit D has shown sensitivities ranging from 71% using IFAT as the gold 
standard [41] and 83% [42] to 91% [15] using microscopy as the gold standard. Specificities ranged 
from 85% using microscopy as the gold standard [42] and 81% as reported by us to 92% [15] if samples 
from individuals who had not travelled to malaria endemic regions were tested. Overall sensitivities 
and specificities were lower than those reported by the instruction manual for kit D (94% and 100%, 
respectively). However, the number of samples was limited in some of these studies (n=11 for 
sensitivity [15]) and sampling approaches varied (i.e. testing suspected malaria patients [42] compared 
to healthy subjects [15] and confirmed malaria patients [15,41]). Thongdee et al. assessed the 
sensitivity and specificity of kit E by testing samples from patients with malaria, patients with fever 
related to other infections and healthy subjects in Thailand [43]. Using malaria diagnosis by 
microscopy as the reference, the sensitivity of kit E was 89% (81 – 95%) and the specificity was 92% 
(86 – 95%) – lower than those reported in the instruction manual (96% and 98%, respectively) as well 
as the specificity reported in this study (98%). 
Although the current study did not test all currently available commercial ELISA kits for antimalarial 
antibody detection, it is promising that one of the five kits accurately described transmission patterns 
in two endemic settings. As costs are an important factor for wide-scale use, it would be advantageous 
if these could be brought down for kit A (currently £1.30/sample excluding laboratory capital expenses 
and technician time). There are some technical advantages of kit A over research-based antibody 
detection protocols. For example, blocking of non-specific binding to malaria antigens in kit A seems 
extremely efficient, demonstrated by the fact that although neat serum is tested, little to no 
background responses are seen (i.e. seroprevalence in those born since the absence of passively 
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detected locally acquired cases in Bataan was 0.6%). Although research-based ELISA protocols dilute 
serum concentrations to 1 in 100s [36] or 1000 [1,3,7,35], which enables use of dried blood spots, 
recent SCRs were higher in Sri Lanka during pre-elimination than those recorded in Bataan in the 
current study [36]. Nevertheless, collecting dried blood spots compared to (neat) serum samples has 
both practical and logistical advantages in field surveys [35]. Ideally, commercial ELISA kits would be 
optimised for use of elution of dried blood spots, or research-based protocols would increase the 
serum concentration while aiming to maintain or reduce non-specific binding. 
 
Conclusion 
One commercial ELISA kit was considered applicable for large-scale use in epidemiological surveys and 
accurately described malaria transmission in a low transmission and pre-elimination setting. 
Commercial ELISA kits detecting antimalarial antibodies may be of use to certify areas malaria-free in 
combination with other metrics such as (passively detected) case counts.   
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Table 1: Assay characteristics for five commercial enzyme-linked immunosorbent assays for antimalarial antibody detection (A-E) according to instruction 
manuals. 
  A B C D E 
Antigenic targets Four recombinant 
antigens for four 
species 
Recombinant 
antigens for four 
species 
Recombinant 
antigens for all P. 
species 
Recombinant 
antigens for four 
species 
CSP and MSP1 
proteins from Pf 
and Pv 
Subclasses IgG, IgM, IgA Not reported IgG, IgM, IgA Not reported IgG, IgM 
Samples/plate* 91 91 89 92 91 
Duration, total 
incubation time in min 
90 min  90 min 150 min 135 min 105 min 
Specificity - all species 
(samples tested) 
96%  
(n=13608) 
100%  
(n=450) 
>98% 
(Not reported) 
100% 
(Not reported) 
98% 
(Not reported) 
Sensitivity - all species 
(samples tested) 
Not reported 
98%  
(n=528) 
>95% 
(Not reported) 
94% 
(Not reported) 
96% 
(Not reported) 
Sensitivity - Pf only 
(samples tested) 
93%  
(n=76) 
98%  
(n=410) 
Not reported Not reported Not reported 
*I.e. all kits use 96-well plates and require a certain number of controls to be run alongside samples. 
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Table 2: Costs per sample, amount of serum needed to run a sample, ease-of-use, specificity and 
cross-reactivity for five commercial enzyme-linked immunosorbent assays for antimalarial antibody 
detection (A-E).  
  
  
A B C D E 
Costs/sample
a
 
  
£1.30 £1.32 £1.84 £2.09 £1.71 
Amount of sample  50 µL 50 µL 150 µL 2 µL 10 µL 
Ease-of-use
b 
  
High High Low Medium High 
Proportion 
negative if: 
     
Malaria 
unexposed 
(n=223)  
99% 
(97-100%) 
99% 
(97-100%) 
98% 
(95-99%) 
81% 
(75-86%) 
98% 
(95-100%) 
Toxoplasma-
infected  
(n=191) 
100% 
(98-100%) 
99% 
(96-100%) 
100% 
(98-100%) 
84% 
(78-89%) 
98% 
(95-99%) 
a Costs per sample are based on running a full 96-well plate of samples after adding necessary controls according 
to kit instruction manuals (see Table 1). Commercial assays were bought in bulk (i.e. 25 plates per brand) in 
January 2016 for Phase I and March 2017 for Phase II. Costs shown here are based on the most recent prices 
from 2017 for assay A, B and E. b Ease-of-use was assessed based on the number of incubation steps, incubation 
time, need for sample preparation and whether reagents are ready-to-use (summarised in Supplementary Table 
1).  
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Figure 1: Map of survey locations in Bataan, the Philippines (a) and Praia, Cape Verde (b-c). The 
square highlighting Cape Verde in (b) is enlarged in (c). 
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Figure 2: Reported malaria cases (a) and antibody metrics using antibody responses recorded by 
enzyme-linked immunosorbent assay A (b-d) in Bataan, the Philippines. In (a) counts of reported 
malaria cases at local health facilities in Bataan according to the source (local or imported) are shown 
over time; data was available for 0 to 12 years prior to data collection (i.e. 2017 – 2005; Provincial 
Epidemiology and Surveillance Unit - Bataan, Malaria Surveillance Report) and 21 to 35 years prior to 
data collection (i.e. 1996 – 1982 [21]). In (b) seroconversion curves of seroprevalence by age are 
shown; solid lines represent the fit of the reversible catalytic model [2], while dots represent observed 
seroprevalence estimates with 95% confidence intervals in vertical segments. Thresholds for 
seropositivity were calculated from the mean of the lower distribution of antibody responses plus 3 
standard deviations using mixtures of skewed normal distributions (black) or according to the kit 
instruction manual (blue). In (c) boxplots of geometric mean antibody titre (i.e. optical density 
corrected for blank responses) are shown over bins of 5 years of age for those aged 60 years or 
younger (range of bin size 63 – 268). The red line represents the age-antibody fit using a super learner 
algorithm as previously described by Arnold et al. [32]: coefficients representing the weight of each 
contributing algorithm were 0.51 for generalized additive model, 0.43 for locally weighted regression 
and 0.06 for the generalized linear model. Horizontal dashed lines represent thresholds for 
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seropositivity according to the mean of the lower distribution of antibody responses plus 3 standard 
deviations using mixtures of skewed normal distributions (black) or according to the instruction 
manual (blue). In (d) seroprevalence is shown by age deciles and gender; dots represent observed 
seroprevalence estimates with 95% confidence intervals in vertical segments. SCR: seroconversion 
rate. 
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Figure 3: Reported malaria cases (a) and antibody metrics using antibody responses recorded by 
enzyme-linked immunosorbent assay A (b-d) in Praia, Cape Verde. In (a) counts of reported malaria 
cases in Praia according to the source (local or imported) are shown over time, data was available 
from 1 to 21 years prior to data collection (i.e. 2016 – 1996) and 22 to 31 years prior to data collection 
(i.e. 1995 – 1986; counts from 1986 – 1987 are for Santiago island [23]). In (b) seroconversion curves 
of seroprevalence by age are shown; solid lines represent the fit of the reversible catalytic model [2], 
while dots represent observed seroprevalence estimates. Thresholds for seropositivity were 
calculated from the mean of the lower distribution of antibody responses plus 3 standard deviations 
using mixtures of skewed normal distributions (black) or according to the kit instruction manual (blue). 
In (c) boxplots of geometric mean antibody titre (i.e. optical density corrected for blank responses) is 
shown over bins of 5 years of age for those aged 60 years or younger (range of bin size 51 – 169). The 
red line represents the age-antibody fit using a super learner algorithm as previously described by 
Arnold et al. [32]: coefficients representing the weight of each contributing algorithm were 0.67 for 
the generalized additive model, 0.31 for the generalized linear model and 0.02 for the antibody 
acquisition model with constant rates. Horizontal dashed lines represent thresholds for seropositivity 
according to the mean of the lower distribution of antibody responses plus 3 standard deviations using 
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mixtures of skewed normal distributions (black) or according to the instruction manual (blue). In (d) 
seroprevalence is shown by age deciles and gender; dots represent observed seroprevalence 
estimates with 95% confidence intervals in vertical segments. SCR: seroconversion rate.
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Table 3: Logistic regression analysis of explanatory factors for seropositivity as recorded by enzyme-linked immunosorbent assay A in Praia, Cape Verde 
and Bataan, the Philippines. 
CV: 1: Varzea; 2: Tira Chapea/Fonton, 3: ASA. Philippines:  1: Laplap; 2: Minanga; 3: Proper; 4: Samuyao. *Youngest reported in Cape Verde 16 years old (range 16-66) and 
in the Philippines 10 years old (10-87). **Removed 36 samples in other areas than main study area. 
 
Distribution pos 
Cape Verde Philippines** 
n/N Unadjusted p Adjusted p N Unadjusted p Adjusted p 
Area 
 1 
2 
3 
4 
 
26/492 
27/550 
14/354 
 
1 
0.93 (0.53 - 1.62) 
0.74 (0.37 – 1.41) 
 
 
0.783 
0.370 
   
35/241 
101/465 
82/563 
62/423 
 
1 
1.20 (0.80 - 1.84) 
1.00 (0.66 - 1.56) 
1.01 (0.65 - 1.60) 
 
 
0.395 
0.988 
0.962 
 
 
 
Age group 
 1-5 
6-15 
>15 
 
1/116 
3/319 
63/961 
 
0.12 (0.19 - 0.96) 
0.14 (0.16 - 0.54) 
1 
 
0.039 
0.001 
 
 
9.14 (2.82 – 56.09) 
1.33 (0.06 – 14.15) 
1 
 
0.002 
0.815 
 
0/236 
3/475 
277/1113 
 
NA 
0.02 (0.00 – 0.05) 
1 
 
0.967 
<0.001 
 
NA 
0.02 (0.01 – 0.06) 
 
0.967 
<0.001 
Gender 
Female 
Male 
 
39/860 
28/536 
 
1 
1.16 (0.70 - 1.90) 
 
 
0.558 
   
121/929 
159/895 
 
1 
1.44 (1.12 – 1.87) 
 
 
0.005 
 
1 
1.56 (1.17 – 2.07) 
 
 
0.003 
Travel                     Yes 
No 
9/77 
58/1250 
1 
0.40 (0.20 – 0.89) 
 
0.014 
   NA 
 
   
IRS 
No 
Yes 
 
46/936 
20/414 
 
1 
0.98 (0.56 - 1.66) 
 
 
0.948 
   
234/1551 
46/273 
 
1 
1.14 (0.80 – 1.60) 
 
 
0.456 
  
Prevention bites 
Repellents 
Other 
None 
 
20/311 
20/620 
24/407 
 
1.10 (0.59 – 2.02) 
0.53 (0.29 – 0.98) 
1 
 
0.768 
0.042 
 
0.99 (0.51 – 1.89) 
0.54 (0.29 – 1.00) 
1 
 
0.979 
0.050 
 
126/898 
149/892 
5/29 
 
1.23 (0.95 – 1.59) 
1.06 (0.35 – 2.56) 
1 
 
0.117 
0.912 
  
Sleep under bed net 
last night                No 
Yes 
 
62/1360 
4/34 
 
1 
2.79 (0.81 – 7.35) 
 
 
0.119 
 
1 
3.60 (0.95 – 10.74) 
 
 
0.034 
 
130/979 
150/845 
 
1 
1.41 (1.09 – 1.82) 
 
 
0.008 
 
1 
1.84 (1.38 – 2.46) 
 
 
<0.001 
Malaria history* 
No 
Yes 
 
59/1369 
7/25 
 
1 
8.63 (3.25 – 20.66) 
 
 
<0.001 
 
1 
6.60 (2.42 – 16.36) 
 
 
<0.001 
 
222/1725 
56/87 
 
1 
12.23 (7.77 – 19.59) 
 
 
<0.001 
 
1 
7.41 (4.61 – 12.14) 
 
 
<0.001 
Antimalarial in last 2 
weeks                     No 
Yes 
 
62/1370 
3/21 
 
1 
3.52 (0.81 – 10.74) 
 
 
0.048 
   
 
 
N/A 
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Supplementary Tables 
Supplementary Table 1: Standard operating procedures for five commercial enzyme-linked 
immunosorbent assays for antimalarial antibody detection (A-E) and composite measure of ease-
of-use. RT: room temperature; min: minutes. 
  A B C D E 
Sample volume 
(Dilution) 
50 µl 
(neat) 
50 µl 
(neat) 
150 µl 
(3:4) 
2 µl 
(1:100) 
10 µl 
(1:101) 
Incubation, min 
(Temperature)  
30 
(37°C) 
30 
(37°C) 
60 
(37°C) 
60 
(RT) 
60 
(37°C) 
Wash 1, n  5 5 4-5 4 3 
Add conjugate 
  
50 µL 
(prepare) 
50 µL #1: 150 µL 
(prepare) 
#2: 100 µL 
100 µL 
(prepare) 
100 µL 
Incubation, min 
(Temperature)  
30 
(37°C) 
30 
(37°C) 
#1: 30  
#2: 30 (37°C) 
60 
(RT) 
30 
(RT) 
Wash 2, n 5 5 4-5 4 3 
Add substrate 50 µL 50 µL 200 µL 100 µL 
(prepare) 
100 µL 
Incubation 
(Temperature)  
30 
(RT) 
30 
(RT) 
30 
(RT) 
15 
(RT) 
15 
(RT) 
Add stop 
  
50 µL 50 µL 100 µL 50 µL 100 µL 
Read plate 
  
450nm 
(reference 
630nm) 
450nm 
(reference 
630nm) 
450nm 
(reference 
630nm) 
450nm 
(blank on air) 
450nm 
(reference 
630nm) 
Ease-of-use 
- Sample 
preparation 
- Incubation 
steps 
- Incubation 
time, min 
- Ready-to-use 
reagents (n/N) 
High 
No 
 
3 
 
90 
 
2/3 
High 
No 
 
3 
 
90 
 
3/3 
Low 
Yes 
 
4 
 
150 
 
3/4 
Medium 
Yes 
 
3 
 
135 
 
1/3 
High 
Yes 
 
3 
 
105 
 
3/3 
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Supplementary Figures 
 
 
 
 
 
 
Supplementary Figure 1: Histogram of antibody responses in Praia, Cape Verde (left) and Bataan, 
the Philippines (right) as recorded by enzyme-linked immunosorbent assay A as well as thresholds 
for seropositivity according to different methods. The optimal number of latent serological 
populations in the antibody data was estimated using mixtures of skewed normal distributions. For 
both settings, the optimal number of components was two using Akaike’s and Bayesian information 
criteria. Solid red lines represent fitted density distributions. Dashed vertical lines represent 
thresholds for seropositivity according to the instruction manual (blue), or the mean of the lower 
distribution plus three (black) or five (red) standard deviations (SD). Seroprevalence estimates with 
95% confidence intervals (CI) using the three SD approach are shown on plots.  
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Supplementary Information I: Toxoplasma diagnosis 
Toxoplasma was diagnosed with nine commercially available Toxoplasma IgG and IgM tests. All 191 
serum samples were tested on:  
- Microgen Mercia Toxoplasma IgG 
- Microgen Mercia Toxoplasma IgM 
- Biorad Platelia Toxoplasma IgG 
- Biorad Platelia Toxoplasma IgM 
- Access Toxoplasma IgG 
- Access Toxoplasma IgM 
- Mast Diagnostics Mastafluor Toxoplasma IgG 
- Mast Diagnostics Mastafluor Toxoplasma IgM 
- Euroimmune Toxoplasma IgG ELISA 
- Euroimmune Toxoplasma IgG IFT 
- Euroimmune Toxoplasma IgM ELISA 
- Euroimmune Toxoplasma IgM IFT 
- Biokit Toxocell Latex 
- Abbott Architect Toxoplasma IgG 
- Abbott Architect Toxoplasma IgG Avidity 
- Abbott Architect Toxoplasma IgM 
- Diasorin Liason Toxoplasma IgG II 
- Biomerieux Vidas Toxoplasma IgG II 
- Biomerieux Vidas Toxoplasma IgG Avidity 
- Biomerieux Vidas Toxoplasma IgM 
- Biomerieux Vidas Toxoplasma Competition 
A sample was considered positive if it tested positive for any of these tests. A subset of samples was 
confirmed by the Sabin Feldman dye test and the IgM immunosorbent agglutination assay at the 
Swansea Toxoplasma Reference Laboratory. 
J. Newham/A. Kitchen; unpublished data  
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Supplementary Information II: Included commercial ELISA kits (A-E) 
Five commercially available ELISA kits for antimalarial antibody detection were evaluated in this study 
(Table SII.1). Instruction manuals of these kits are included in Appendix C. 
Table 1: ID (A-E) and brand names for five commercial enzyme-linked immunosorbent assays for 
antimalarial antibody detection. 
Kit Name 
A Trinity Biotech 
B NewBio 
C DiaPro  
D Cellabs 
E NovaTec / NovaLisa 
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Supplementary Information III: Epidemiological characterisation 
using kit E 
Data analyses were performed in STATA version 15. Antibody levels recorded by kit E were similar 
across age groups and thus did not show the expected increase over age in both Praia, Cape Verde 
and Bataan, the Philippines (Figure SIII.1). This was reflected in seroprevalence as recorded responses 
all existed around the threshold for positivity. This resulted in high seroprevalence in Cape Verde for 
all ages and for children in the Philippines (Table SIII.1 and Figure SIII.2), while transmission patterns 
as recorded by locally reported malaria cases suggest low transmission in Cape Verde (Figure 3a) as 
well as an absence of transmission in recent years in the Philippines (Figure 2a). 
 
Table 1: Seroprevalence as recorded by enzyme-linked immunosorbent assay E in Praia, Cape Verde 
and Bataan, the Philippines (overall and by age category). Seropositivity was determined according 
to the kit instruction manual. 
 Philippines Cape Verde 
Overall 
 
Age category, years:       
1/5 
6/15 
>15 
11% 
 
 
4% (10/235) 
10% (47/479) 
14% (154/1132) 
51% 
 
 
30% (35/116) 
48% (153/319) 
54% (524/961) 
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Figure 1:  Boxplots of antibody levels recorded by enzyme-linked immunosorbent assay E over age 
categories and sub-regions in Praia, Cape Verde and Bataan, the Philippines. OD: Optical Density 
corrected for blank responses.  
0
1
2
3
4
0
1
2
3
4
1/5 6/10 11/15 16/25 26/40 41/max 1/5 6/10 11/15 16/25 26/40 41/max
1/5 6/10 11/15 16/25 26/40 41/max
Varzea Tira Chapea/Fonton
Achada Santo Antonio
A
n
ti
b
o
d
y
 l
e
v
e
l 
(O
D
)
Cape Verde
0
1
2
3
4
0
1
2
3
4
1/5 6/10 11/15 16/25 26/40 41/max 1/5 6/10 11/15 16/25 26/40 41/max
1/5 6/10 11/15 16/25 26/40 41/max 1/5 6/10 11/15 16/25 26/40 41/max
LAPLAP MINANGA
PROPER SAMUYAO
A
n
ti
b
o
d
y
 l
e
v
e
l 
(O
D
)
The Philippines
177 
 
 
 
 
Figure 2: Seroconversion curves using seropositivity as recorded by enzyme-linked immunosorbent 
assay E in Praia, Cape Verde and Bataan, the Philippines. Seropositivity was determined according to 
the kit instruction manual. 
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Additional File: Application and performance of a research-based 
ELISA protocol in which antigens were pooled in epidemiological 
characterising of malaria transmission patterns at low transmission 
and pre-elimination 
In Chapter 6 results for the epidemiological application of five commercially available ELISAs are 
discussed (i.e. ease-of-use, specificity, cross-reactivity, the volume of serum needed to run an 
experiment and costs). In addition, their performance in characterising transmission in a low 
transmission (Praia, Cape Verde) and pre-elimination (Bataan, the Philippines) setting was shown. In 
this addition, these results are presented for a research-based ELISA protocol in which antigens were 
pooled.  
Methods 
Samples from malaria unexposed individuals as well as Toxoplasma-infected individuals were tested. 
Furthermore, samples from a low, unstable transmission setting (Praia, Cape Verde; n=1432) and a 
pre-elimination setting (Bataan, the Philippines; n=2050) were tested. For details on study populations 
and sample collection see Chapter 6. 
A previously described research-based ELISA protocol [1] was performed with the following 
modifications (SOP included in Appendix D). To optimally capture exposure, a pool of five P. 
falciparum antigens was used: AMA-1, MSP-119, MSP-2 Dd2, MSP-2 CH150/9 and GLURP-R2. To 
increase throughput and reduce costs, samples were run in single. A positive control standard curve 
using a Tanzanian hyperimmune sera pool was run in duplicate on every plate starting at 1:10 with a 
5-fold dilution over six steps and samples were tested at a final concentration of 1:1000. Optical 
density (OD) measures were read with a spectrophotometer (Dyson Technologies) at a wavelength of 
450nm. OD measures were corrected for blank responses (hereafter: ODcorr). As standard curves of 
hyperimmune sera did not saturate at the bottom asymptote, these could not be used to adjust ODcorr 
measures for plate-to-plate variation. Seropositivity for samples from endemic settings was identified 
as described in Chapter 6 for commercial ELISA kit results (i.e. the sn package in R).  
Results 
The time to run the assay was considerably longer for the research-based ELISA compared to 
commercially available ELISAs (Table 1). Costs and the amount of serum needed to run an experiment 
were minimal for the research-based ELISA (Table 2). Seroprevalence results for malaria unexposed 
(i.e. representing specificity) and Toxoplasma-infected (i.e. representing cross-reactivity) individuals 
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are not shown as thresholds for seropositivity could not be defined. Thresholds for seropositivity in 
the research-based ELISA are usually based on finite mixture models for endemic populations whereby 
two distribution are identified, and the lower distribution is assumed to be formed by seronegatives. 
The mean of the lower distribution plus three standard deviations is then used as the threshold for 
seropositivity. As the malaria unexposed individuals and Toxoplasma-infected individuals should not 
show antimalarial antibodies, only one distribution could be identified. Another approach is to use the 
mean plus three standard deviations of antibody responses from an unexposed population. As the 
malaria unexposed individuals and Toxoplasma-infected individuals are such populations, by default 
the ~2.5% outliers on the right-hand side of the normal distribution would therefore be identified as 
seropositive. 
Scatter plots of ODcorr measurements recorded by the research-based ELISA and the commercial ELISA 
kit A show minimal correlation between the two assays (Figure 1). In Cape Verde and the Philippines 
two mixtures were estimated, however both distributions were assumed be seronegative in Cape 
Verde (i.e. mean ODcorr values for these distributions were 0.04 and 0.14) and the Philippines (0.105 
and 0.293), Figure 2. Therefore, seroprevalence and seroconversion curves could not be estimated. 
Conclusion 
The research-based assay was not optimised sufficiently as it did not identify negative and positive 
populations accurately (Figure 1 and 2). This may be due to insufficient optimisation of antigen and 
serum concentrations as well as insufficient blocking efficiency for non-specific binding on the 
research-based ELISA. Therefore, differentiation of individuals exposed and unexposed to malaria was 
not possible in both Praia, Cape Verde and Bataan, the Philippines. As shown in Chapter 6, commercial 
ELISA kit A was able to identify a seropositive population in both settings and serological results 
overlapped with transmission patterns assessed through passively detected case counts. However, 
ELISA kit A is relatively expensive compared to the research-based ELISA (Table 2) and the antigens 
tested for are unknown. Although the overall duration of the research-based ELISA protocol is ~48 
hours, this includes 32 hours incubation and 40 plates can be run per experiment thus technician time 
per plate is similar to commercial ELISAs. Therefore, if the research-based ELISA could be improved, 
the low costs and ability to adjust antigen pools for specific settings and/or use-case scenarios would 
be advantageous compared to commercial ELISAs. 
 
References 
1. Corran PH, Cook J, Lynch C, Leendertse H, Manjurao A, Griffin J et al. Dried blood spots as a source 
of anti-malarial antibodies for epidemiological studies. Malaria J. 2008;7:195.  
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Table 1: Assay characteristics for five commercial (A-E) and the research-based enzyme-linked immunosorbent assays for antimalarial antibody detection 
according to instruction manuals. 
  A B C D E Research-based 
Antigenic targets Four recombinant 
antigens for four 
species 
Recombinant 
antigens for four 
species 
Recombinant 
antigens for all P. 
species 
Recombinant 
antigens for four 
species 
CSP and MSP1 
proteins from Pf 
and Pv 
Five Pf 
recombinant 
antigens* 
Subclasses IgG, IgM, IgA N/A IgG, IgM, IgA N/A IgG, IgM IgG 
Samples/plate 91 91 89 92 91 80 
Duration 90 min  90 min 150 min 135 min 105 min ~48 hours 
Plates/run 4 4 4 4 4 40 
Specificity according 
to manual - all species 
96% (n=13608) 100% (n=450) >98% 100% 98%  N/A 
Sensitivity according 
to manual - all species 
N/A 98% (n=528) >95% 94% 96%  N/A 
Sensitivity according 
to manual - Pf only 
93% (n=76) 98% (n=410) N/A N/A N/A  N/A 
For antigen abbreviation see Chapter 5, Table 1. Ig: immunoglobulin, N/A: not applicable, min: minutes, Pf: Plasmodium falciparum.  
* AMA-1, MSP1-19, MSP 2 Dd2, MSP2 CH150/9 and GLURP-R2. 
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Table 2: Costs per sample, amount of serum needed to run a sample, ease-of-use, specificity and 
cross-reactivity for five commercial (A-E) and the research-based enzyme-linked immunosorbent 
assays for antimalarial antibody detection.  
  
  
A B C D E Research-
based 
Costs/sample
a
 
  
£1.30 £1.32 £1.84 £2.09 £1.71 £0.13 
Amount of 
sample  
50 µL 50 µL 150 µL 2 µL 10 µL 2 µL 
Ease-of-use
b 
  
High High Low Medium Medium Medium 
Proportion 
negative if: 
      
Malaria 
unexposed 
(n=223)  
99% 99% 98% 82% 98% N/A 
Toxoplasma-
infected, non-
exposed 
(n=191) 
100% 99% 100% 84% 98% N/A 
a Commercial assays were bought in bulk (i.e. 25 plates per brand) in January 2016 for Phase I and March 2017 
for Phase II. Costs shown here are based on the most recent prices from 2017 for assay A, B and E. 
b Ease-of-use was assessed based on the number of incubation steps, incubation time, need for sample 
preparation and whether reagents are ready-to-use (summarised in Supplementary Table 1).  
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Figure 1: Paired optical density (OD) measurements using the research-based enzyme-linked 
immunosorbent assay (ELISA) protocol and commercial ELISA kit A in participant samples from 
Praia, Cape Verde (left) and Bataan, the Philippines (right). OD measures were corrected for blank 
responses. Open dots represent participant samples while black lines represent thresholds for 
seropositivity. 
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Figure 2:  Density plots of optical density (OD) measurements using the research-based enzyme-
linked immunosorbent assay (ELISA) protocol in participant samples from Praia, Cape Verde (left) 
and Bataan, the Philippines (right). OD measures were corrected for blank responses. Red lines 
represent estimated densities of mixtures of skewed normal distributions. In Cape Verde and the 
Philippines two mixtures were estimated, however both distributions were assumed be seronegative 
in Cape Verde (i.e. mean ODcorr values for these distributions were 0.04 and 0.14) and the Philippines 
(0.105 and 0.293).
 
 
Supplementary Table 1: Standard operating procedures for five commercial (A-E) and the research-based enzyme-linked immunosorbent assays for 
antimalarial antibody detection. 
  A B C D E Research-
based 
Sample volume 
(dilution) 
50 µl 
(neat) 
50 µl 
(neat) 
150 µl 
(3:4) 
2 µl 
(1:100) 
10 µl 
(1:101) 
2 µl 
(1:1000) 
Incubation 
  
30 
(37°C) 
30 
(37°C) 
60 
(37°C) 
60 
(RT) 
60 
(37°C) 
Overnight 
(4°C) 
Wash 1  5 5 4-5 4 3 5 
Add conjugate 
  
50 µL 
(prepare) 
50 µL #1: 150 µL 
(prepare) 
#2: 100 µL 
100 µL 
(prepare) 
100 µL 1:15,000 
(prepare) 
Incubation 
  
30 
(37°C) 
30 
(37°C) 
#1: 30 + #2: 30 
(37°C) 
60 
(RT) 
30 
(RT) 
180 
(RT) 
Wash 2  5 5 4-5 4 3 5 
Add substrate 50 µL 50 µL 200 µL 100 µL 
(prepare) 
100 µL 100 µL 
Incubation 
  
30 
(RT) 
30 
(RT) 
30 
(RT) 
15 
(RT) 
15 
(RT) 
15 
(RT) 
Add stop 
  
50 µL 50 µL 100 µL 50 µL 100 µL 50 µL 
Read plate 
  
450nm 
(reference 
630nm) 
450nm 
(reference 
630nm) 
450nm 
(reference 
630nm) 
450nm 
(blank on air) 
450nm 
(reference 
630nm) 
450nm 
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Chapter 7: Discussion 
Summary of findings 
The overall aim of this thesis was to assess the performance of antimalarial antibody metrics for active 
detection (i.e. cross-sectional populations) in low transmission and pre-elimination settings. Part of 
this is a better understanding of the performance of existing malaria metrics at low transmission to 
identify if/where adjunct metrics are needed. Therefore, Chapter 3 discussed the discordance 
between RDT, PCR and microscopy prevalence estimates. It showed that cross-sectional P. falciparum 
parasite rate estimates by microscopy and RDT were similar (microscopy detects 87%, 74–102% of 
RDT-positive infections), while RDTs miss 41% (26–66%) of PCR-confirmed infections. These 
observations are consistent with previous observations in a meta-analysis comparing microscopy and 
PCR prevalence measures [1,2]. These RDT- and/or microscopy-undetected infections were defined in 
this thesis as low-density infections. The proportion of low-density infections increased with age and 
decreasing transmission intensity. This suggests that a substantial proportion of malaria infections 
remain undetected by routine diagnostics in low transmission settings and adjunct metrics are 
desirable if/where low-density infections need to be identified (discussed below). 
Chapter 4 aimed to determine if low-density infections induced measurable antibody responses (IgG). 
It showed that detectable antibody responses were determined in 96% of previously naïve CHMI 
participants one month after exposure to low-density P. falciparum infections. It should be noted that 
this was a limited dataset in terms of sample size, genetic diversity of humans (i.e. only from non-
endemic settings) and the range of parasite densities acquired. However, it is promising that nearly all 
participants showed measurable IgG responses one to seven months post-CHMI (≥94% of the 
participants) while peak parasite densities remained below 200 parasites/µl; and that antibody 
responses were detected to a small subset of targets (4 out of 40 analysed) in all participants with 
measurable antibody responses. Even at the low range of peak parasite densities recorded, there was 
a strong dose-response relationship between cumulative parasite density and MSP-119 as well as a 
combined measure of the four most responsive antibodies. Thus, a combination of a few antibody 
responses would have been sufficient in identifying recent exposure to low-density infections in these 
participants, and, possibly, the individuals with low-density infections in Chapter 3. 
In commercial ELISA kits, antimalarial antibodies are assessed to a combination of antigenic targets by 
coating wells with a pool of multiple antigens. Responses to individual targets could not be assessed 
but results represent a more general estimate of previous exposure to malaria infection, usually used 
to assess the risk of transfusion-transmitted malaria in donor blood products. In Chapter 6, one of five 
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commercial ELISA kits evaluated was considered applicable for large-scale screening of serum samples 
in epidemiological surveys and antibody responses recorded with this kit accurately reflected 
transmission patterns in a low transmission and pre-elimination setting. The use of this standardised 
serological tool may help as an adjunct measure in supporting claims of the cessation of malaria 
transmission in previously endemic areas. 
 
Technical considerations 
Antibody responses were detected by microarray in Chapter 4 and ELISA in Chapter 6. Multiplex 
methods, such as protein microarray, have the advantage of screening for multiple antibodies in a 
sample simultaneously compared to responses to single targets (or a pool) in ELISA. Multiplex bead 
assays (MBA), another platform for multiplex detection, are increasingly used in malaria research 
owing to their low costs in acquisition compared to protein microarray (Chapter 1). A standardised 
assay is a pre-requisite for its use in surveillance. However, since the MBA is relatively new to the 
malaria research field (i.e. first applied to P. falciparum antibody detection in 2006 [3]), various 
methods for normalisation of collected data have been described to standardise results [4,5]. In Haiti, 
an MBA was used for antibody detection in large-scale malaria transmission surveys which aimed to 
directly inform control and elimination policies (discussed below). As such, a protocol was designed 
with an increased throughput: the OneStep protocol in which participant or control/standard serum 
samples (human IgG) and secondary antibody (anti-human IgG) were incubated simultaneously 
(Rogier et al. in preparation, Appendix A). Chapter 5 contained a discussion of technical considerations 
for antimalarial antibody detection using the OneStep MBA protocol. Antibody measures in 
participant samples were shown to increase for all, and saturate for some, antigens if the OneStep 
protocol was used as compared to a conventional protocol. A statistical approach was applied to 
adjust for this discordance in antibody measures for participant samples. In addition, Chapter 5 
described the retrospective quality control of data collected with the OneStep protocol in three large-
scale malaria transmission surveys by assessing assay precision over time. Inter-plate variability of 
antibody measures in hyperimmune positive control samples repeated on each plate (i.e. representing 
assay precision) was considered acceptable. However, inter-plate variability seemed to increase over 
time, i.e. by the third survey, possibly due to long-term storage of reagents. 
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Low-density infections: do they matter? 
Since the development of RDTs in the 1990s (reviewed in[6]) they have seen improvements in ease-
of-use [7] and accuracy [8] and have seen wide-spread use as a routine diagnostic in patient care [9] 
as well as epidemiological research [10]. For P. falciparum, species-specific RDTs detecting circulating 
HRP2 antigen are most widely used, while LDH-based tests are genus-specific [7]. RDTs are considered 
user-friendly and fast [7], though they have been designed to detect parasite densities greater than 
200 parasites/µl [11]. We now know that most infections exist below this lower limit of detection, 
especially at low transmission (Chapter 3). As the number of countries experiencing low transmission 
or in pre-elimination increases [12] with our ability to detect lower parasite densities by using ultra-
sensitive methodologies involving high blood volumes [13], the question on which limit of detection 
is needed to eliminate rises. In addition, the time in which identification of these infections can be 
achieved and therefore the finances needed, need to be considered. Alere™ have developed a highly-
sensitive RDT (hs-RDT) with a reported limit-of-detection that is 10-fold more sensitive than 
conventional HRP2-based RDTs (cRDT). Laboratory assessments of its performance are promising, 
however results from a limited number of studies to date following field deployment vary [14]. 
Moreover, reports of parasites with HRP2/HRP3 deletions [15,16] indicate caution as their spread 
would cause a major public health problem owing to the wide-spread use of HRP2-detecting RDTs 
[17,18]. Nevertheless, if these deletions are monitored and field deployment of hs-RDTs shows results 
consistent to laboratory assessments, the use of hs-RDTs may improve the identification of previously 
undetected populations. 
Determining the contribution of low-density to onwards transmission and therefore the answer to the 
question “Do they matter?” was not the aim of this thesis but it is an important part of future work. 
Some have hypothesised/argued their importance [19]: 1) low-density infections can increase in 
density at a later timepoint and therefore should be treated [20], 2) although countries have 
eliminated without attempts to test and treat low-density infections, these may not be representative 
of remaining endemic settings, and 3) studies aiming to test-and-treat with conventional diagnostics 
have failed to reduce transmission. Data from observational studies in which human-to-mosquito 
infectiousness is measured experimentally (i.e. by feeding colony-reared mosquitoes on humans or 
human blood) is limited, especially due to challenges in finding low-density infections at low 
transmission (i.e. proportionally they make up the majority of infections, but absolute numbers are 
low). In Thailand, approximately one in five infections with submicroscopic gametocyte densities for 
either P. falciparum or P. vivax were able to infect mosquitoes [21]. Modelling exercises suggest that 
by increasing the limit-of-detection of RDTs from 200 to 20 parasites/µl, the detected proportion of 
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the infectious reservoir (i.e. the combined infectivity to mosquitoes of the whole population weighted 
by how often each individual is bitten) would increase from 55% to 83% [22]. This was based on data 
collected in Burkina Faso and parameter estimates from Wu et al. (Chapter 3). It should be noted that 
routinely identifying low-density infections might not be needed as MDA strategies have proven 
successful in decreasing malaria transmission in certain settings [23]. Nevertheless, it is important to 
determine the contribution of low-density infections (and whether there is a difference in 
symptomatic or asymptomatic patients) to infectivity of mosquitoes, and thus onwards transmission, 
in order to design future control and elimination policies. Although PCR-based techniques detect these 
infections, they are considered impractical for field surveys due to the high costs, long processing time 
and the lack of appropriate facilities in many endemic countries [24]. Antibody responses may be an 
option in identifying those exposed to (low-density) malaria infections, however, we need to create a 
better understanding of the kinetics of antibody responses, their consistency across populations and 
the limitations or methods of standardisation of antibody detection platforms. 
 
Multiplex antibody detection: less is more 
Taking high-throughput to its limits  
The application of multiplex antibody detection assays to malaria research has increased the 
serological information collected from one experiment while decreasing technician time and the 
quantity of reagents needed. In this thesis, two of these techniques, protein microarray and MBA, are 
discussed. As mentioned above, MBA is increasingly applied by malaria research groups owing to their 
low cost of acquisition and ease-of-use compared to protein microarray. Several have described 
optimisation methods for the MBA such as the detection of Ig subclasses [25] and IgG isotypes [25,26] 
as well as the optimisation of control standards of hyperimmune sera [25] and analytical methods to 
assess inter-plate variation using these types of standards [4,5]. Further simplifying the MBA protocol 
to increase throughput, and decrease technician time and the chance of errors, has also been 
described (Rogier et al., in preparation, Appendix A). This is of specific use in settings where results 
need to be readily available. In the Malaria Zero project in Haiti, serological results were needed 
rapidly to directly inform control and elimination policies. Antimalarial antibody metrics from rapid 
assessment surveys were used to stratify areas for MDA (see below) and will be used to assess its 
impact on malaria transmission in these areas. 
A simplified MBA protocol was used for the Malaria Zero surveys in Haiti: the recently described 
OneStep protocol in which sample (human IgG) and secondary (anti-human IgG) are incubated 
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simultaneously (Rogier et al., in preparation, Appendix A). The OneStep MBA protocol involves two 
wash steps compared to 4-5 in conventional protocols (Rogier et al., in preparation, Appendix A). This 
improves the ease-of-use of the assay and limits the chance of errors (e.g. loss of beads through 
washing steps). The OneStep protocol was also considered to have a higher throughput compared to 
the conventional protocol. However, the information in the data collected is limited as antibody 
measures are increased which led to a saturation of MFI measurements at the upper limit-of-detection 
of the MAGPIX® machine (Chapter 5). The saturation in MFI measurements in participant samples was 
more pronounced for immunogenic targets, as expected, while less immunogenic targets did not 
reach saturation (Chapter 5 and Appendix B). Assessing antibody responses to a panel of antigens 
simultaneously means that assay conditions are not optimised individually and thus likely not ideal for 
all. Even though higher responses were recorded by the OneStep compared to the conventional 
protocol, seroprevalence estimates were largely the same for malarial antigens (Rogier et al., in 
preparation, Appendix A). If the aim of the antibody data collected is stratification of study areas, 
binary measures may be sufficient, especially combined with age as it creates SCR estimates which 
have shown a strong correlation with transmission as determined by EIR (Chapter 1, [27]). However, 
if the aim is to inform the effect of policies, seropositivity may not be sufficient, as antibody levels 
decline prior to changes in seroprevalence [28]. The saturation seen at the higher range of MFI 
measurements using the OneStep protocol may limit the ability to detect a decrease in antibody titres 
after the implementation of interventions, especially if pre- and post-intervention surveys are close 
together in time (i.e. months to a year).  
Although the work presented in this thesis has discussed a statistical approach to adjust for the 
discordance in antibody measures between protocols for participant samples (Chapter 5); the data to 
support this approach was collected at the start of serological data collection for Survey 1. The 
precision of the assay, assessed by MFI measurements in repeated samples on each plate, decreased 
over time for some antigenic targets (in Survey 3). Therefore, the use of this statistical approach to 
transform antibody responses may not be advisable for certain antigens from Survey 3 onwards. 
Moreover, during my PhD work I have found that, practically, the limiting factor in the time needed to 
collect data using the MBA lies in reading plates on the MAGPIX® machine rather than in sample 
processing. Thus, in my opinion, the OneStep protocol does not increase the throughput of samples 
assayed. Nevertheless, there may be applications of this protocol if 1) the aim is to collect data on 
seropositivity alone and 2) where results need to be readily available to directly inform control or 
elimination policies, or for stratification of risk. 
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Translating results into an actionable response 
Commercial ELISAs have been standardised for diagnostic use as well as some research-based 
protocols. An example is the ELISA protocol used within our research group, which has been used in a 
variety of endemic settings for almost 15 years [29]. The selected antigens used to coat commercially 
available ELISAs that detect antimalarial antibodies are unknown for most kits. Some indicate the use 
of MSP1 and CSP. Based on the results from Bataan, the Philippines, discussed in Chapter 6, the 
antigens used in kit A likely induce antibody responses with relatively long half-lives as high 
seroprevalence was recorded in adults under the absence of local transmission in the past decades. A 
research-based ELISA protocol detecting antibodies to a pool of five antigens (including AMA1 and 
MSP1-19) showed similar though overall lower patterns of age-specific seroprevalence (Chapter 6, 
Additional File). These antibody responses are suitable in describing the cessation of transmission in 
certain contexts (e.g. in Bataan as age-specific seroconversion curves mirrored a drop from over 800 
to 141 reported cases in 1994-1995 after which cases were almost exclusively imported) but likely not 
all. If the cessation of transmission is more recent, age-specific seroconversion curves may not detect 
it as shown by relatively high estimates of the recent SCR in Sri Lanka pre-elimination [30]. This could 
be due to both technical (i.e. assay-specific) or analytical (e.g. sample size/power [31]) issues. Antibody 
responses with shorter half-lives, as described by Helb et al. [32], may be better suited to describe 
(the absence of) recent transmission in these settings. Ideally multiplex antibody detection assays 
would not be used to assess responses to a wide range of malarial targets if the aim is sero-
surveillance, owing to the difficulty in translating these data into actionable responses to date. A 
subset of targets, which, in singular or combined, can represent recent, intermediate and historical 
exposure, would be advantageous. 
It should be noted that there is limited evidence to date on antigens that are associated with recent 
exposure (i.e. over the past month to one year; Table 1), and even less for those associated with 
intermediate exposure (i.e. over the past 1-5 or 1-10 years). This information is essential if the aim is 
to be able to identify different time windows of past exposure to infection in one cross-section as 
suggested by Greenhouse et al. [27]. Helb et al. identified responses to three antigens that accurately 
identified whether an individual had been infected within the last 30-365 days (Hyp2, GexP and 
exonuclease), while continuous responses to a combination of six antigens accurately estimated an 
individual’s malaria incidence in the prior year [32]. However, this cohort was Ugandan children and 
it is unclear if the same performance would have been observed in adults. Recently described data 
from a cohort in the Gambia [33], which also included adults, showed some overlap in the antigens 
associated with recent exposure as identified by Helb at al. but the accuracy was lower, and the 
identified antigens were different between individuals of all ages and children. Studies from Kenya 
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and Cambodia also identified antigens associated with recent exposure [34,35]. None of these studies 
used the same combination of 1) antigen panel assessed, 2) antibody detection assay, 3) sample 
dilution, or 4) age range of the study population, thus making it difficult to draw conclusions from 
these results (Table 1). Moreover, it is likely that genetic differences (in human and parasite 
populations) across endemic settings would induce different immune responses (discussed to some 
extent in Chapter 1) thus more cohort studies are needed to confirm these results.  
Once the optimal target(s) are determined for historical, intermediate and recent exposure to malaria 
infection, these can be tailored to a specific use-case scenario and setting. A single target or a 
combination of targets can be assessed using a multiplex assay, (pooled) ELISA or LFA15 depending on 
the context. The latter two options would be relevant where results have to be readily available (e.g. 
stratification of areas of risk or a decentralised immediate response). These would also be 
advantageous for malaria control programme managers, as binary responses (i.e. yes/no) are easier 
to interpret and respond to than multiple continuous measures. If separate responses to a panel of 
targets is better suited for a specific use-case-scenario (e.g. measuring the impact of interventions), 
and therefore a multiplex assay is the most suitable option, the goal should be to expand the panel 
with antigens from other pathogens of interest in the setting, such as vaccine-preventable diseases, 
helminths or other parasitic infections to maximise the use of this platform. An overview of the most 
appropriate serological endpoints using antimalarial antibody metrics per use-case-scenario is shown 
in Figure 1. 
                                                          
15 We have tested a newly developed LFA detecting a malaria-related antibody in several low 
transmission areas, but data were not included due to prototype and patent issues. 
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Table 1: Overview of published evidence of antibody responses to antigens associated with recent naturally acquired Plasmodium falciparum infections. 
NB only antigens that are part of the panel analysed in this thesis (Chapter 5-6) are included in this table. Furthermore, only studies with repeated sampling 
of the same individuals were considered. Recent is defined as ≤1 year. 
Description Target 
(design) 
Detection 
assay 
Sample 
dilution 
Antigens/peptide Country Study design Age 
range 
Ref 
Accurately predicted day 
since last infection (30, 90 
or 365 days)a  
Recombinant 
antigens 
(IVTT) 
Micro-
array 
1:200 Hyp2 
GexP  
 
HSP40 
Etramp 4 
Uganda Cohort 3-7 
years 
[32] 
Predicted incidence 
(symptomatic malaria) in 
previous year 
Recombinant 
antigens 
(IVTT) 
Micro-
array 
1:200 Hyp2 
Etramp 5 
CSP 
MSP2 
Etramp 4 
Uganda Cohort 3-7 
years 
[32] 
Accurately predicted day 
since last infection (30, 90 
or 150 days)b 
Recombinant 
antigens 
(bespoke) 
MBA 1:400 GexP 
HSP40 
Etramp 5 
AMA1 
The 
Gambia 
Cohort All 
ages 
[33] 
Accurately predicted day 
since last infection (30, 90 
or 150 days)c 
Recombinant 
antigens 
(bespoke) 
MBA 1:400 SBP1 
GexP 
Rh5 
Etramp 5 
EBA175 
HSP40 
AMA1 
MSP1-19 
GLURP 
The 
Gambia 
Cohort 1-15 
years 
[33] 
Estimated half-life <1 yeard Peptides and 
recombinant 
antigens 
(bespoke) 
MBA 1:200 GLURP-R2 
MSP1-19 
CSP (peptide) Cambodia Re-sampled 
population from 
repeated cross-
sectional surveys 
2-50 
years 
[34] 
Estimated half-life <1 yeare Recombinant 
antigens 
(bespoke) 
MBA 1:200 CSP (peptide)  Kenya Cohort All 
ages 
[35] 
Estimated half-life <1 yeare Recombinant 
antigens 
(bespoke) 
MBA 1:200 AMA-1 
EBA175 
 
MSP1-19 
GLURP-R2 
Kenya Cohort <5 or 
<10 
[35] 
a Area under the curve (AUC) of ROC > 0.85. b AUC of ROC ≥ 0.78. c AUC of ROC ≥ 0.79.  d Estimations based on antibody loss over ~600 days (~20 months). e Estimations based 
on antibody loss over ~14 months. IVTT: in vitro transcription and translation; MBA: multiplex bead assay 
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Figure 1: Previously described use-case-scenarios of antimalarial antibody detection and hypothesised optimal serological endpoints using antimalarial 
antibody metrics. a Use-case -scenarios were described by Greenhouse et al. (under review, Gates Open Research).
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Multiplexing across diseases rather than within 
Arnold et al. recently advocated for “an integrated approach to surveillance of population immunity 
and infectious disease transmission” [36]. They highlighted that in the last 10 years Uganda has 
completed 20 or more population-based sero-surveillance surveys across multiple infectious diseases. 
Integrating these serological surveys can greatly reduce costs and time. MBA protocols require as little 
as 1 µl of serum to determine up to 50 or 100 antibody responses simultaneously. This means that 
collection of participant samples could be reduced by expanding antigen panels to include more 
pathogens, if study designs are appropriate for the pathogen of interest. This would greatly reduce 
survey and laboratory costs but may also help in ensuring continued community participation as 
repeated sampling of the same populations may lead to reduced participation (reviewed in [37]), 
especially as transmission decreases and perceptions about personal and/or perceived risks change 
[38]. Moreover, an integrated approach in collecting serological data may also engage scientists in 
exchanging statistical approaches to determine disease transmission and changes therein. Currently, 
MBA platforms seem to mostly be applied to assess multiple antibodies within one disease, such as in 
the Malaria Zero project in Haiti, while future work should focus on including antigens from other 
pathogens to make optimal use of the information gathered in cross-sectional surveys. 
In addition to multiplex antibody detection, MBA platforms have also been used to detect human 
polymorphisms to identify inherited blood disorders associated with malaria [39] or Plasmodium 
polymorphisms to identify sensitivity to antimalarial treatment [40]. Furthermore, protocols have 
been described to detect parasite antigen in samples such as HRP2 and pLDH to validate RDT survey 
results [41], thereby making it possible to screen for infections with possible HRP2/HRP3 deletions 
more efficiently [42]. Creating and/or optimising these protocols to include the detection of other 
pathogens would further integrate surveillance methods. 
 
Limitations 
PhD project-specific issues 
The order in which the projects are presented in this thesis does not represent the chronological order 
in which they occurred. Ideally, the results from the CHMI project (Chapter 4), and/or other 
longitudinal studies conducted within our and other research groups, would have informed the 
selection of the antigen pool tested by ELISA in Chapter 6 (Additional File). However, the commercial 
ELISA project preceded the CHMI project, thus a pool of well-characterised antibodies with relatively 
long half-lives was used. The pooled, research-based ELISA protocol would be ideal for rapid 
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assessment of population exposure history due to its ease-of-use and relatively low cost per sample. 
Moreover, national laboratories in endemic settings generally have access to a spectrophotometer 
due to its application in monitoring or diagnosing other infectious diseases such as Human 
Immunodeficiency Virus (HIV). Future work to optimise the research-based ELISA protocol for 
antimalarial antibody detection would include increasing serum concentration as well as blocking non-
specific binding to improve discrimination between negative and positive antibody responses. The 
advantage of the research-based ELISA compared to commercial ELISAs is the fact that antigen pools 
(i.e. those with long or short half-lives) can be selected for specific use-case-scenarios and settings.  
The projects presented in this thesis were not all part of the original outline of chapters. My role in 
the Malaria Zero project, in which I worked part-time throughout my PhD, included analyses and 
interpretation of antibody responses from cross-sectional surveys to inform control and elimination 
strategies. In addition, I focused on a comparison of antibody metrics by survey design: a cross-
sectional household survey compared to a survey in easy-access-groups, such as children at schools 
or visitors of health facilities. A one-year delay in cross-sectional surveys due to hurricane Matthew 
causing landfall in Haiti in September 2016, as well as programmatic issues, led to the exclusion of 
these projects from the thesis. Throughout the duration of my PhD I have presented posters at 
scientific conferences detailing the use of the antibody data collected in Haiti in informing control and 
elimination policies. These posters are included in Appendix E and represent an overview of the 
statistical approaches I have learned during this time (e.g. STATA and later R Studio). Although not 
included in this thesis, working with these data and for the Malaria Zero project has helped me 
advance my understanding of antimalarial antibody metrics at low transmission. It has also given me 
additional field experience, such as in the setup, deployment and performance of cross-sectional 
surveys. 
 
Limitations in the use of antimalarial antibodies at low transmission 
Outstanding issues in the use of antimalarial antibody metrics were detailed in Figure 4, Chapter 1. 
Some of these were focussed on low transmission and pre-elimination. The performance of 
antimalarial antibodies in detecting recent exposure to low-density infections has been demonstrated 
in this thesis (Chapter 4), although a limited sample size was available, and the results need to be 
confirmed following naturally-acquired infections. However, for antibody metrics to be applied to 
sero-surveillance in low transmission and pre-elimination settings, there are still some unresolved 
issues.  
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Firstly, the most accurate standardised method to determine thresholds for seropositivity needs to be 
established. In low transmission and pre-elimination settings, an approach in which latent 
distributions are identified in the antibody data (such as finite mixture models) may not be 
appropriate. Specifically, the decreasing seropositive population may not be sufficient to identify as a 
separate population and they may instead be identified as outliers of the seronegative population (i.e. 
false-negatives). Or vice versa, outliers of the seronegative population may be identified as a separate 
population and incorrectly be identified as seropositive (i.e. false-positives). This may especially affect 
antibodies with short half-lives which were hypothesised to be able to detect (the absence of) malaria 
transmission earlier than those with long half-lives. Therefore, alternative methods should be 
explored to harness the information gained from short-term antibodies reliably. It may instead be 
more appropriate to identify thresholds using the antibody responses of an unexposed reference 
seronegative population from the same or similar setting (e.g. those in metropolitan cities of endemic 
countries where transmission can be lower or even non-existent, or those who have migrated to non-
endemic settings).  
Secondly, although antibodies with short half-lives representing recent exposure may be 
advantageous for certain use-case-scenarios compared to those with long half-lives (e.g. to measure 
the effect of interventions), they may not be ideal at low transmission or pre-elimination. An 
advantage of antimalarial antibodies metrics is the smaller sample sizes needed to measure 
transmission as they represent cumulative exposure. However, as transmission declines to less than 1 
case per 1000, short-lived antibodies (i.e. <1 year) would arguably require similar sample sizes to those 
detecting clinical cases , and perhaps even asymptomatic infection, in order to measure transmission.   
 
Conclusion 
The data presented in thesis has furthered our understanding of the use of antimalarial antibody 
metrics to determine malaria transmission at low transmission and pre-elimination. It has concluded 
that 1) RDT detects about 40% of all PCR-confirmed infections and RDT-undetected infections 
increased with age and decreasing transmission intensity; 2) low-density infections in previously naïve 
CHMI participants induced measurable IgG responses and antibodies to only four targets represented 
all participants with a measurable IgG response; 3) MBA protocols can be optimised for particular use-
case-scenarios (rapid screening of large sample numbers); 4) a commercially available, standardised 
ELISA kit, in which antimalarial antibodies were measured to a pool of antigens, was applicable to 
large-scale screening of samples in epidemiological surveys, and responses detected by this kit 
mirrored transmission patterns represented by passively detected case counts in a low transmission 
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and pre-elimination setting. The work in this thesis has also identified areas of possible future 
research: 1) to determine the contribution of low-density infections in humans to infectivity of 
mosquitoes, and therefore onward transmission; 2) to determine which antibodies reflect recent 
exposure following naturally acquired low-density infections in endemic populations; 3) to improve 
pooled ELISA protocols by either optimising commercial ELISA kits for the use of lower serum 
concentrations (i.e. enabling the use of dried blood spots), or by optimising research-based protocols 
by increasing serum concentrations with more efficient blocking of non-specific binding, pooling 
markers of recent exposure and/or detecting IgM antibodies. 
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Methods  
Samples. Serum and dried blood spot (DBS) samples (n=796 DBS with 712 paired serum) 
from serosurvey in Haiti were collected in April and May 2017. Informed consent was 
collected from all participants enrolled if older than 18 years, and informed consent from a 
legal guardian if the participant was younger than 18. Fingerprick whole blood was collected 
in EDTA-coated capillary tubes (Safe-T-Fill™ Capillary Blood Collection Systems: EDTA, # 
07 7053, RAM Scientific Inc., Yonkers, NY) and whole blood was spotted on Whatman 903 
ProteinSaver cards (GE Healthcare) on the same day. Blood remaining in the tube was 
stored at 4oC until later centrifugation (5000g for 2min) to fractionate and allow removal of 
serum. The study protocol was approved by Haiti Ethical Review Committee; CDC 
investigators were determined not to be engaged with human subjects.  
DBS from all studies were eluted in Buffer B (PBS containing 0.5% BSA, 0.05% 
Tween 20, 0.02% sodium azide, 0.5% polyvinyl alcohol, 0.8% polyvinylpyrrolidone and 0.5% 
w/v E. coli extract) by incubation overnight at 4 degrees. Liquid serum from the Haiti survey 
was directly diluted in Buffer B.  
 
Antigens and Couplings. All antigens were covalently linked to MagPlex (magnetic) 
microspheres (Luminex Corp., Austin, TX) as described previously 25. Briefly, beads were 
pulse vortexed, transferred to a microcentrifuge tube and centrifuged for 5 minutes at 
16,000g. Supernatant was removed and beads were washed with 0.1M sodium phosphate, 
pH 6.2 (NaP). Beads were activated by suspending in NaP with 50 mg/mL of EDC (1-ethyl-
3-[3-dimethylaminutesopropyl] carbodiimide hydrochloride) and 50 mg/mL sulfo-NHS (sulfo 
N-hydroxylsulfosuccinimide) and incubating with rotation for 20 minutes at room temperature 
(RT) protected from light. After wash with antigen-coupling buffer (optimized for each 
antigen), beads were suspended in antigen coupling buffer with the appropriate 
concentration of antigen and rotated for 2 hours at RT protected from light. Beads were 
washed and suspended in PBS with 1% bovine serum albumin (BSA) and incubated for 30 
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minutes at RT by rotation. Beads were then washed with storage buffer (PBS, 1% BSA, 
0.02% sodium azide and 0.05% Tween-20) and and suspended in storage buffer containing 
protease inhibitors (200 µg/mL Pefabloc, 200 µg/ml EDTA, 1 µg/mL pepstatin A and 1 µg/mL 
leupeptin) and stored at 4°C. Coupled beads were counted with either a hemocytometer or 
Luna cell counter using manufacturer’s instructions (Logos Biosystems Annandale, VA). 
 
Bead-based Immunoassay Protocols. The standard MBA was performed as described 
previously 25. Briefly, the standard assay was performed in flat bottom BioPlex Pro 96 well 
plates (Bio-Rad, Hercules, CA). Washes between incubation steps used a handheld magnet 
(Luminex Corp). After addition of 200µl wash buffer (PBS, 0.05% Tween-20, PBST) to each 
well, wash buffer was left in each well for one minute to allow bead magnetization before 
inverting the plate to evacuate the wells of liquid. Beads (250,000 beads/antigen/plate) were 
suspended in Buffer A (PBS, 0.5% BSA, 0.05% Tween-20, 0.02% NaN3) and 50 µL bead 
mix added to each well. Plates were washed two times with PBST and 50 µL of sample was 
added to each well and incubated with shaking at room temperature for 90 minutes. After 3 
washes with PBST, beads were incubated with biotinylated anti-human IgG (1:500, Southern 
Biotech, Birmingham, AL) and biotinylated anti-human IgG4 (1:625, Southern Biotech). 
Plates were incubated for 45 minutes and washed 3 times with PBST.  Streptavidin 
conjugated to phycoerythrin (PE) (1:200 Invitrogen, Waltham, MA) was added to detect 
bound secondary antibody. After a 30 minute incubation, wells were washed 3 times with 
PBST and incubated in Buffer A for 30 minutes under light shaking to remove any loosely 
bound antibodies. Samples were resuspended in 100µl PBS and fluorescence data collected 
immediately on the MAGPIX with Bio-Plex Manager™ MP software with a target of 50 beads 
per region per well. Median fluorescence intensity (MFI) signal was generated for a minimum 
of 50 beads/region, and background MFI from wells incubated with Buffer B was subtracted 
from each sample to give a final value of MFI minus background (MFI-bg) for analysis. 
The OneStep assay was performed with the same samples and reagents used in the 
standard MBA protocol. In 5mL Buffer A, a bead mix was prepared with all regions included, 
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and 50uL bead mix was pipetted into a BioPlex Pro plate. Beads were washed 2x with 
100uL PBST, and 50uL reagent mix (in 5mL Buffer A: 1:500 anti-human IgG, 1:625 anti-
human IgG4, 1:200 streptavidin-PE) was added to all wells, then 50µL samples (or controls) 
were added to the appropriate wells. Plates were incubated overnight with gentle shaking at 
room temperature and protected from light. The next morning (after ~16h total incubation 
time), plates were washed 3x, and beads resuspended with 100µL PBS and read on the 
MAGPIX machine. MFI signal was generated for a minimum of 50 beads/region, and 
background MFI from wells incubated with Buffer B was subtracted from each sample to give 
a final value of MFI-bg. After reading, plates were evacuated of sheath fluid, and beads 
resuspended in 100µL PBS, sealed, and stored at 4oC to allow testing of the same plates at 
a later date. A flow chart comparing the two protocols is shown in Figure 1. 
 
Statistical Analysis. Statistical analyses were performed in SASv9.4 (SAS Institute, Cary, 
NC). Direct comparisons between MFI-bg values using the two protocols were represented 
by k-nearest-neighbor-based local regression (LOESS) curves created through the SGPLOT 
procedure with cubic interpolation and a degree of 2. Log-transformed MFI-bg values were fit 
to a two-component finite mixture model by the FMM procedure with normal distribution and 
maximum likelihood estimation outputs. Linear regression was used to estimate change in 
MFI-bg values following storage for one week or one month after completion of the OneStep 
protocol.   
 
Results  
Selection of Samples and Antigens Used for the Study. To broadly evaluate the impact 
of modifying the assay protocol on the fluorescence detection signal (Fig. 1), we tested a 
diverse set of 511 samples from multiple global locations representing an array of different 
infectious disease settings: United States, Brazil, Ghana, Tanzania, and Mozambique16. For 
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collection of IgG data, a total of 36 antigens were chosen representing 25 pathogens (viral, 
bacterial, and parasitic) capable of causing disease in humans.  
 
Use of the Finite Mixture Model Statistical Approach to Categorize Dataset. We used 
the 2-component finite mixture model (FMM) statistical approach to estimate the antibody 
distributions in two putative subpopulations for each antigen: seropositive and seronegative 
17,18. This statistical approach was chosen as it could be applied to the MFI-bg data for all 36 
antigens used in this study, and the maximum likelihood estimation (MLE) outputs could be 
directly compared between the two protocols.   
 
Comparison of Prevalence Estimates from Integrated Serosurvey in Haiti. To compare 
seroprevalence estimates that would be generated for defined study population using 
different laboratory protocols or sample types, we used samples collected during an 
integrated serosurvey in Haiti. Serum and dried blood spot (DBS) samples from the same 
persons were assayed by the standard and OneStep protocols for IgG against a select panel 
of eight antigens representing malaria, strongyloidiasis, and lymphatic filariasis. Similar to 
the findings from the sample set representing multiple countries, the assay signals 
generated by using the OneStep protocol to test Haitian samples were amplified for all eight 
antigens included in the integrated serosurvey regardless of the serum or DBS sample type 
(Supplementary Fig. 4). In applying the 2-component FMM for the eight antigens, increased 
distance was seen between the means of the two components for data for 7 of 8 antigens 
tested in serum, and 7 of 8 antigens tested from DBS (Supplementary Fig. 5, Supplementary 
Table 3). Estimates for seroprevalence in the Haiti study population were largely unchanged 
if different sample types or test protocols were used (Table 2). Notable exceptions were the 
higher seroprevalence estimates (greater than 1.28 standard deviations) observed for use of 
the OneStep protocol with serum samples for NIE, Bm14, and Bm33NS antigens.          
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Tables 
Table 2. Seroprevalence Estimates for Percent of Population Positive to IgG against 
Specified Antigens, Haiti 2017 
Antigen  
Serum  Dried Blood Spot  Average Estimate 
(s.d.) Standard OneStep Standard OneStep 
Pf MSP1-19 45.7 38.8 46.6 42.4 43.4 (3.54) 
Pv MSP1-19 5.8 8.9 7.0 7.9 7.4 (1.32) 
Pm MSP1-19 6.2 8.3 6.3 5.9 6.7 (1.10) 
PfCSP 16.4 18.8 15.6 13.8 16.2 (2.07) 
NIE 3.4 6.2 2.9 1.8 3.6 (1.87) 
Wb123 4.5 5.3 2.8 6.7 4.8 (1.63) 
Bm14 18.6 29.1 13.8 16.4 19.5 (6.71) 
Bm33NS 15.6 42.1 14.1 13.1 21.2 (13.95) 
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Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Protocols for standard and OneStep MBA. Each step of assay protocols is 
outlined with time between steps indicated in the arrows.  
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Supplementary Information 
 
Supplementary Table 3. Estimates and Fitting Statistics from Finite Mixture Model 
Comparing Standard to OneStep Protocols, and Blood Elutions to Serum, from Haiti 
Samples 
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Supplementary Figure 4. Median Fluorescence Intensity Minus Background (MFI-bg) Signal Comparison for Serum and Dried Blood 
Spot Sample Types from a Serosurvey in Haiti, Assayed Using Standard or OneStep Protocols. Relationship between two protocols 
visualized as LOESS curves with cubic interpolation and 95% confidence intervals in shading, with y=x reference as a hashed line.  
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Supplementary Figure 5. Fittings to Two-Component Finite Mixture Models for Antigen Data from Haiti Study Collected by both Assay 
Protocols for both Serum and Dried Blood Spot Sample Types. Histograms are displayed for log-transformed MFI-bg values for the entire 
sample set as generated by the standard and OneStep protocols for serum and dried blood spot data with percent of sample set on y-axes.  
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Supplementary Figure 5. Continued. 
215 
 
 
Supplementary Figure 6. Different Incubation Times for the OneStep Assay and MFI-
bg Assay Signal for Selected Malaria Antigens. Hyperimmune serum for malaria antigens 
was serially-diluted and incubated for 15, 30, 60, or 90 minutes with OneStep protocol, or 
assayed with standard protocol.  
 
  
216 
 
 
 
Supplementary Figure 7. Illustration of the Positive Shift in the Assay Signal 
Distribution for Seropositive Persons as Observed for IgG Data against Most Antigens 
when Using the OneStep Protocol as Compared to the Standard Protocol. Signal 
distribution for seronegative persons remained largely unchanged.  
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Appendix B: Transformation of antibody responses between the 
OneStep and Stepwise multiplex bead assay protocols for remaining 
antigenic targets 
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Transformation of antibody responses between the OneStep and Stepwise multiplex bead assay 
protocols for MSP2 CH150/9. Median fluorescence intensity (MFI) measurements were corrected for 
background reactivity of blank responses and natural log-transformed. For antigen abbreviations see 
Chapter 5, Table 1. The sigmoidal relationship of paired measurements was obtained using 804 
samples processed on the One-Step and the Stepwise assay protocol (Rogier et al., in preparation, 
Appendix A). (a) Scatter plot of paired measurements with 4 or 5-parameter logistic regression in red 
line. Curve parameters of sigmoidal fits are shown in Supplementary Table 2. Recorded MFI 
measurements lower than blank responses were replaced with the average of blank MFI values of the 
One-Step protocol across all plates by antigen. Measurements from the One-Step protocol were 
transformed using the sigmoidal fit. Samples that fell below the bottom asymptote or over the upper 
asymptote, were replaced by the lowest and highest values that the model could estimate. (b) Scatter 
of transformed responses compared to measurements using the Stepwise protocol. (c) Histograms of 
One-Step, Stepwise and transformed antibody measurements. (d) Box plots of age-specific One-Step, 
Stepwise and transformed antibody measurements. 
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Transformation of antibody responses between the OneStep and Stepwise multiplex bead assay 
protocols for MSP2 Dd2. For legend see page 218. 
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Transformation of antibody responses between the OneStep and Stepwise multiplex bead assay 
protocols for Etramp 4 Ag 2. For legend see page 218. 
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Transformation of antibody responses between the OneStep and Stepwise multiplex bead assay 
protocols for Etramp 5 Ag 1. For legend see page 218. 
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Transformation of antibody responses between the OneStep and Stepwise multiplex bead assay 
protocols for GEX-P. For legend see page 218.  
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Transformation of antibody responses between the OneStep and Stepwise multiplex bead assay 
protocols for GLURP-R0. For legend see page 218.  
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Transformation of antibody responses between the OneStep and Stepwise multiplex bead assay 
protocols for GLURP-R2. For legend see page 218. 
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Transformation of antibody responses between the OneStep and Stepwise multiplex bead assay 
protocols for H103. For legend see page 218.  
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Transformation of antibody responses between the OneStep and Stepwise multiplex bead assay 
protocols for HRP2. For legend see page 218.  
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Transformation of antibody responses between the OneStep and Stepwise multiplex bead assay 
protocols for HSP40. For legend see page 218.  
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Transformation of antibody responses between the OneStep and Stepwise multiplex bead assay 
protocols for Hyp2. For legend see page 218.  
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Transformation of antibody responses between the OneStep and Stepwise multiplex bead assay 
protocols for MSP1-19. For legend see page 218.  
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Transformation of antibody responses between the OneStep and Stepwise multiplex bead assay 
protocols for LSA-1. For legend see page 218.  
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Transformation of antibody responses between the OneStep and Stepwise multiplex bead assay 
protocols for rCSP. For legend see page 218.  
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Transformation of antibody responses between the OneStep and Stepwise multiplex bead assay 
protocols for SBP1. For legend see page 218.  
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Transformation of antibody responses between the OneStep and Stepwise multiplex bead assay 
protocols for SEA. For legend see page 218. 
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Appendix C: Instruction Manuals of Commercially Available Enzyme-
linked Immunosorbent Assays  
1. Commercial ELISA A (page 235) 
2. Commercial ELISA B (page 237) 
3. Commercial ELISA C (page 239) 
4. Commercial ELISA D (page 246) 
5. Commercial ELISA E (page 249)  
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Appendix D: Standard Operating Procedure for the Research-based 
Combined Antigen Enzyme-linked Immunosorbent Assay 
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Appendix E: Posters Presenting Results from the Malaria Zero Project 
for Scientific Conferences Visited During my PhD programme 
 
1. Keystone Symposia. Malaria: From Innovation to Eradication. Kampala, Uganda, 19-23 
February 2017. (Attended). Page 266. 
2. American Society of Tropical Medicine & Hygiene. Annual Meeting 2017. Baltimore, Maryland, 
USA, 5-9 Nov 2017. (Not attended – poster presented by Eric Rogier, PhD). Page 267. 
3. Multilateral Initiative on Malaria (MIM). 7th MIM Pan African Malaria Conference. Dakar, 
Senegal, 15-20 April 2018. (Attended). Page 268. 
4. American Society of Tropical Medicine & Hygiene. Annual Meeting 2018. New Orleans, 
Louisiana, USA, 28 Oct-1 Nov 2018. (Attended). Page 269. 
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